Bortezomib (PS-341)

製品コードS1013 別名：LDP-341, MLM341

Bortezomib (PS-341)化学構造

分子量(MW)：384.24

Bortezomib (PS-341) is a potent 20S proteasome inhibitor with Ki of 0.6 nM. It exhibits favorable selectivity towards tumor cells over normal cells.

サイズ 価格(税別)  
JPY 11620.00
JPY 44820.00
JPY 111220.00
お問い合わせ バルク問合せ

文献中Selleckの製品使用例(149)

カスタマーフィードバック(25)

  • Immunoblot analysis of cell lysates from the indicated cell lines treated with GNE-6776 (2 μ M for 18 h), either alone or in combination with a UAE1 inhibitor MLN-7243 (5 μ M for 45 min) or the proteasome inhibitor bortezomib (5 μ M for 45 min) as indicated.

    Nature, 2017, 550(7677):534-538. Bortezomib (PS-341) purchased from Selleck.

    Indisulam dependent degradation of RBM39 can be blocked by bortezomib, a proteasome inhibitor. Cells were pretreated with indicated concentrations of bortezomib for 2 hours, followed by 6 hours of treatment with 2 μM indisulam. The effect of bortezomib is attenuated in a bortezomib resistant cell line.

    Science, 2017, eaal3755. Bortezomib (PS-341) purchased from Selleck.

  • Wild-type mice fed as indicated were injected with vehicle (10% DMSO, pH 7.4 PBS) or bortezomib (5 mg/kg bodyweight). Livers were collected 16 hr later for quantitative PCR analysis of indicated genes (n = 4–5). *p < 0.05 bortezomib effect and #p < 0.05 Chol-Diet effect by two-way ANOVA.

    Cell, 2017, 171(5):1094-1109. Bortezomib (PS-341) purchased from Selleck.

    Effect of different proteasome inhibitors on dysferlin expression and on membrane resealing in cultured primary myoblasts. Primary myoblasts from patient 2 harboring a homozygous Arg555Trp DYSF mutation that were treated with the indicated amounts of bortezomib for 24 hours. Western blots of protein extracts were stained with anti-dysferlin antibodies and with anti–a-tubulin antibody as loading control.

    Sci Transl Med 2015 6(250), 250ra112. Bortezomib (PS-341) purchased from Selleck.

  • Pharmacologic inhibition of the proteasome blocks proplatelet formation in murine and human megakaryocytes. Human megakaryocytes were pretreated with vehicle or bortezomib, and megakaryocytes producing proplatelets (PP) were examined. Shown are representative transmission images and representative confocal images with wheat germ agglutinin (WGA; red) and phalloidin (green) staining. Scale bars: 50 um.

    J Clin Invest 2014 124(9), 3757-66. Bortezomib (PS-341) purchased from Selleck.

    Effects of NF-kB inhibition on cell proliferation and apoptosis in Foxp3cKO prostate. A. Top left panels: Representative H&E staining of PIN lesions in ventral prostates of 60-week-old PBS- or bortezomib-treated Foxp3cKO littermates. Scale bar, 50 祄. Right graph: Quantification of Ki67-positive cells identified by IHC analysis (bottom left panels) as a measure of cell proliferation, performed with Scion Image software. Horizontal lines represent the average values. The p value was determined by two-tailed t test. B. Representative western blots showing p65 and nuclear p65 (N-p65) expression in prostates at 12 hours after LPS injection in 45-week-old PBS- or bortezomib-treated mice. C. Quantification of Bcl2l1 and Traf1/2 mRNA expression as a percentage of Hprt expression measured in microdissected mouse prostate epithelial cells by qPCR at 12 hours after LPS injection in 45-week-old PBS- or bortezomib-treated mice. Horizontal lines represent the average values. The p values were determined by two-tailed t test. D. Left panels: Representative images of TUNEL assays performed on prostates from PBS- or bortezomib-treated mice at 60 weeks of age. Insets show the apoptotic cells (green) in prostate glands. Scale bar, 100 祄. Right graph: Quantification of apoptotic cells in the ventral and dorsolateral prostates of PBS- or bortezomib-treated mice at 45 and 60 weeks of age. Horizontal lines represent the average values. The p value was determined by two-tailed t test. cKO, PB4-Cre4+Foxp3flox/y; wks, weeks; B/P, ratio of the mean value from bortezomib-treated mice to the mean value in PBS-treated mice. All experiments were repeated two times. Wks, weeks.

    Cancer Res 2015 75(8), 1714-24. Bortezomib (PS-341) purchased from Selleck.

  • Immunofluorescence showing HDAC4 localization in mouse primary osteoblasts treated with vehicle or PTH alone or in the presence of bortezomib. Primary osteoblasts treated with vehicle, PTH, or PTH plus bortezomib for 2 h using anti-HDAC4 and anti-b-actin antibodies.

    J Cell Biol 2014 205(6), 771-80. Bortezomib (PS-341) purchased from Selleck.

    Inhibition of proteasome and lysosome or silencing of VCP and co-factors lead to the accumulation of OP-puro-labeled DRIPs adjacent to or within SGs. HeLa cells were co-treated for 45 min with OP-puro and arsenite (Ars.); where indicated, cells were pretreated with bortezomib (Bort.) overnight and/or ammonium chloride (NH4Cl) for 2 h 15 min. Cells were fixed and labeled with Alexa594-Azide and anti-TIA-1.

    Cell Death Differ 2014 21(12), 1838-51. Bortezomib (PS-341) purchased from Selleck.

  • Immunofluorescence analysis for Ser536 p-NF-κB cellular localization of RS4;11cells treated with CX-4945 (5 μM) and bortezomib (2.5 nM) either alone or in combination. Cells were treated, collected at 22 h and reacted with an antibody to Ser536 p-NF-κB which was revealed by a Cy3-conjugated secondary antibody. DAPI was used to label nuclei.

    Oncotarget, 2015, 51: S659-S660. Bortezomib (PS-341) purchased from Selleck.

    Control wild-type and Fmn2–/–oocytes observed at different stages of meiotic maturation [prophase I (Pro I), NEBD, 3 hours and 8 hours after NEBD] using anti-Fmn2. wt + Bortezo, wild-type oocytes treated with 0.1μM Bortezomib for 90 minutes before fixation. All oocytes were observed using the same settings and the images treated the same way (three independent experiments). Red arrows indicate cortical labeling. Scale bar: 10μm.

    Development 2011 138, 2903-2908. Bortezomib (PS-341) purchased from Selleck.

  • Cell viability of HCT116 cells treated with a single drug or with the addition of leucovorin.

    Sci Rep, 2017, 7(1):682. Bortezomib (PS-341) purchased from Selleck.

    (B–C) LNCaP (B) and LNCaP-AI (C) cells were transiently transfected with sPLA2-IIa(-800)-Luc (0.5 μg). The cells were then treated with Erlotinib (20 μM), Gefitinib (20 μM), Lapatinib (20 μM), CI-1033 (8 μM), LY294002 (20 μM) and Bortezomib (20 μM) without or with EGF (100 ng/ml) for 24 h. Luciferase assay was performed according to a standard protocol with Renilla luciferase as an internal control. Data are presented as the mean (±SD) of duplicate values of a representative experiment that was independently repeated for five times.

    Carcinogenesis 2010 31, 1948–1955. Bortezomib (PS-341) purchased from Selleck.

  • LNCaP-AI cells were starved in 1% stripped medium for 24 h. The cells were then treated with Erlotinib (20 μM), Gefitinib (20 μM), Lapatinib (20 μM), CI-1033 (8 μM), LY294002 (20 μM) and Bortezomib (20 μM) for 24 h. Cell culture medium was collected from each sample and subjected to ELISA for sPLA2-IIa. The condition medium samples were diluted 10 times for ELISA. Average of duplicate samples was converted to nanogram per milliliter against standard curve. The data represent one of five repeated experiments.

     

     

    Carcinogenesis 2010 31, 1948–1955. Bortezomib (PS-341) purchased from Selleck.

    PS-341 impairs FPV replication in A549 cells. (A and B)A549 cells were either pretreated for 1 h with different concentrations of PS-341 or with solvent only or were left untreated. Then, cells were infected with FPV at an MOI of 0.001 (A) or 0.05 (B). After virus inoculation cells were posttreated with different concentrations of PS-341. (A) At 24 h p.i. supernatants were obtained and progeny virus titers were measured by standard plaque assay. (B)Proteasome activity and the ability of PS-341 to inhibit the proteasome was determined 24 h p.i. (C) A549 cells were pretreated with 50 nM PS-341 or solvent or left untreated for 1 h. Afterwards cells were infected with FPV at an MOI of 0.0005. Subsequent to virus inoculation cells were posttreated with 50 nM PS-341 or solvent or left untreated. After the indicated times p.i.supernatants were obtained and progeny virus titers were determined by standard plaque assay. Arrow bars in all experiments represent standard deviations of three independent experiments.

    J Virol 2010 84, 9439–9451. Bortezomib (PS-341) purchased from Selleck.

  • Early steps of viral replication within the first replication cycle are affected. (A) For time-of-addition kinetics analysis, A549 cells were either left untreated or were pretreated for 10 h or 1 h with 50 nM PS-341 before infection and additionally posttreated after infection. Cells were infected with FPV at an MOI of 0.005. After virus inoculation cells were posttreated with 50 nM PS-341. Then the proteasome inhibitor was added after virus inoculation (10 h, 1 h, and 30 min) or it was added at the different times p.i. as indicated (1 h, 2 h, 4 h, 6 h, and 8 h; cells were not pretreated before infection). At 9 h p.i. supernatants were obtained and progeny virus titers were determined by standard plaque assay. Shown is one representative experiment out of three independent experiments. (B) A549 cells were pretreated with 50 nM PS-341 or left untreated for 1 h. Afterwards cells were infected with avian FPV or human PR8 at an MOI of 1. Subsequent to virus inoculation cells were posttreated with 50 nM PS-341 or left untreated. After the indicated times p.i. cells were lysed and analyzed by Western blotting for accumulation of viral proteins polymerase PB1 and matrix protein M1. Cellular protein ERK2 served as a control to demonstrate equal amounts of protein loading. Shown is one representative blot out of three independent experiments.

     

     

    J Virol 2010 84, 9439–9451. Bortezomib (PS-341) purchased from Selleck.

    A549 cells were treated with PS-341 at 50 nM for the indicated times or left untreated. Western blotting was performed with total cell lysates, using phospho-specific antibodies against JNK and the transcription factors c-Jun and ATF-2 or loading controls, respectively.

     

     

    J Virol 2010 84, 9439–9451. Bortezomib (PS-341) purchased from Selleck.

  • Western blot of extracts of infected cells treated with different proteasome inhibitors at different concentrations, reacted with the indicated antibodies. p53 was used to monitor proteasome inhibition, and actin was used as a loading control.

     

     

    J Virol 2011 85, 2781–2792. Bortezomib (PS-341) purchased from Selleck.

    Time window treatment with proteasome inhibitors. (A) Scheme of the experiment performed with MA104 cells exposed to virus (OSU; MOI, 3) for 1 h and analyzed at the starting point and endpoint of the indicated time window treatments with DMSO, MG132, or bortezomib. (B) Western blot of cellular lysates derived from cells infected for the indicated time periods and treated with the proteasome inhibitors or DMSO. NI, noninfected cells. Blots were reacted with the indicated antibodies; p53 was used to monitor proteasome inhibition, and actin was used as a loading control.

    J Virol 2011 85, 2781–2792. Bortezomib (PS-341) purchased from Selleck.

  • Fluorescence analysis of viroplasm formation on NSP5-EGFP cells infected with rotavirus (OSU; MOI, 3) and treated or not treated with MG132 (10 M) or bortezomib (10 M) at different times p.i., as indicated. Cells were analyzed at the starting points (1 h, 3 h, 5 h, 7 h) and endpoints (9 h) of the inhibitor’s window treatment.

     

     

    J Virol 2011 85, 2781–2792. Bortezomib (PS-341) purchased from Selleck.

    Quantification of the accumulation of viroplasms in infected NSP5 -EGFP/MA104 cells. At different times p.i., cells were treated for 4 h with DMSO or the indicated proteasome inhibitor and the number of viroplasms/cell was quantified at the starting (1 h, 3 h, 5 h; white bars) and endpoints (5 h, 7 h, 9 h) of treatment.

     

     

    J Virol 2011 85, 2781–2792. Bortezomib (PS-341) purchased from Selleck.

  • The stable cell line HepAD38 was incubated for 18 h in the presence of the indicated amount of Bortezomib. The medium was removed and replaced by medium containing Bortezomib dissolved in PBS. In case of the control cells the same amount of PBS was added to the medium. 4 h later this procedure was repeated and again 14 h later the supernatant was collected. The amount of viral particles was quantified by real time PCR. HBV-genome quantification was done using COBAS® AmpliPrep/COBAS® TaqMan® HBV test (Roche Diagnostics GmbH, Mannheim, Germany) according to the manufacturer’s instructions. The assay shows relative values (the value for untreated control cells was arbitrarily set as 1) that are based on three independent experiments. The cell viability was analyzed by MTT assays. For does up to 50 nM no significant effect on cell viability was observed within 18h, for 100 nM the proportion of metabolically active cells was reduced to 83%.

    J Biol Chem 2010 285, 41074-41086. Bortezomib (PS-341) purchased from Selleck.

    HLC-1 cells were treated with IFN-gamma (30 ng/ml) and Bortezomib (0-10 nM) for 3 h. After washing with PBS, the cells were cultured for another 45 h in the fresh medium. After 48 h incubation, PD-L1 expression was analysed by flow cytometry (n =3).

    Int Immunopharmacol, 2018, 54:39-45. Bortezomib (PS-341) purchased from Selleck.

  • Proteasome inhibition effect on biotinylation of MHC-Iα. (a) WB-ra of cellular extracts of HEK293 cells co-transfected with BAP-MHC-Ia and cyt-BirA (control) and, where indicated, with US2 or US11 in the absence (2) or presence of MG132 (MG; 50 μM for 4 h) or Bortezomib(Bort.; 50 μM for 4 h).

    PLoS One 2011 6, e23712. Bortezomib (PS-341) purchased from Selleck.

     

    KKU-M213 was treated with BTZ as indicated. Total cell lysate ( a) and nuclear extract (b) were prepared. Actin and γ -tubulin were loading controls for total and nuclear proteins, respectively.

    2011 Mireia Vila Gasull University of Porto. Bortezomib (PS-341) purchased from Selleck.

  • Mireia Vila Gasull University of Porto. 2011;Mireia Vila Gasull . Bortezomib (PS-341) purchased from Selleck.

製品安全説明書

Proteasome阻害剤の選択性比較

生物活性

製品説明 Bortezomib (PS-341) is a potent 20S proteasome inhibitor with Ki of 0.6 nM. It exhibits favorable selectivity towards tumor cells over normal cells.
ターゲット
20S proteasome [1]
(Cell-free assay)
0.6 nM(Ki)
体外試験

Bortezomib, a boronic acid dipeptide, is a highly selective, reversible inhibitor of the 26S proteasome which primarily functions in the degradation of mis-folded proteins and is essential for the regulation of the cell cycle. Exposure to Bortezomib has been shown to stabilize p21, p27, and p53, as well as the proapoptotic Bid and Bax proteins, caveolin-1, and inhibitor κB-α, which prevents activation of nuclear factor κB-induced cell survival pathways. Bortezomib also promotes the activation of the proapoptotic c-Jun-NH2 terminal kinase, as well as the endoplasmic reticulum stress response. Alteration of the levels of these cellular proteins leads to inhibition of proliferation, migration, and promotion of apoptosis of cancer cells. [2] Bortezomib is shown to penetrate into cells and inhibit proteasome-mediated intracellular proteolysis of long-lived proteins with a concentration that inhibits 50% of the proteolysis of ∼0.1 μM. The average growth inhibition of 50% value for Bortezomib across the entire panel of 60 cancer cell lines derived from multiple human tumors from the US National Cancer Institute (NCI) is 7 nM. Treatment of PC-3 cells with Bortezomib (100 nM) for 8 h results in the accumulation of cells in G2-M, with a corresponding decrease in the number of cells in G1. Bortezomib kills PC-3 cells at 24 and 48 hr with IC50 of 100 and 20 nM, respectively. Bortezomib induces nuclear condensation at 16–24 hr after treatment. Bortezomib treatment leads to PARP cleavage in a time-dependent manner with concentrations as low as 100 nM being effective at 24 hr. [1]
細胞データ
Cell Lines Assay Type Concentration Incubation Time Formulation Activity Description PMID
MCF-7 NFr4WYtEgXSxdH;4bYMhSXO|YYm= NWi3NpNIPTBizszN MUG0PEBp M1rwR2ROW09? M2nPZ2tqdGy|IHPlcIx{KGK7IH3vdoUhfGijbjC5PUU> MnX1NVA1QTl4NEO=
OVCA 429 MlTvSpVv[3Srb36gRZN{[Xl? NEHUWno{ODBibl2= NGrQTYs1QCCq MVXEUXNQ NHPpZ5BFcXO{dYD0d{BqdnSjY4SgcZVtfGmlZXzseYxieiC2dX3vdkB{eGincn;p[JM> Mn3BNVA6QTl5Nk[=
RPMI8226 NUWyUmt2T3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm= NEPQVIMyODBibl2= MmeyOFghcA>? MlPBSG1UVw>? MnGyTWM2OD1|MDDuUS=> MYWxNVMxPjR6OR?=
Dox40 NHvyVFRIem:5dHigTY5pcWKrdHnvckBCe3OjeR?= M1LYc|ExOCCwTR?= MonCOFghcA>? MlPISG1UVw>? MU\JR|UxRTRyIH7N NVvhcoRZOTF|ME[0PFk>
MR20 NI\rcFFIem:5dHigTY5pcWKrdHnvckBCe3OjeR?= M2fiPFExOCCwTR?= MlnvOFghcA>? NHPrdpRFVVOR NVe3UWplUUN3ME2yNEBvVQ>? NE\zTZEyOTNyNkS4PS=>
LR5 M3fnOWdzd3e2aDDJcohq[mm2aX;uJGF{e2G7 M3jVNVExOCCwTR?= NE\sNos1QCCq MnjQSG1UVw>? NVi3S2lkUUN3ME2yNEBvVQ>? M{DKU|EyOzB4NEi5
U266 NF7WVZVIem:5dHigTY5pcWKrdHnvckBCe3OjeR?= M1zNcVExOCCwTR?= NV;jdFl[PDhiaB?= MX7EUXNQ NF3HbZNKSzVyPUOgcm0> MoLENVE{ODZ2OEm=
IM-9 NV7TNoFKT3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm= Mn7lNVAxKG6P M1PsbFQ5KGh? MWTEUXNQ NGHMNmRKSzVyPU[gcm0> MUSxNVMxPjR6OR?=
Hs Sultan NIXnOZNIem:5dHigTY5pcWKrdHnvckBCe3OjeR?= MoXaNVAxKG6P NIrzZ4g1QCCq NUnjU5BzTE2VTx?= NFq5VFFKSzVyPUKwJI5O NGTRNJUyOTNyNkS4PS=>
PAM-LY2 M2X3[2Z2dmO2aX;uJGF{e2G7 NYL5fWFsOTByIH7N M{\FblEzKGh? MWnEUXNQ MUXJcohq[mm2czDOSk3PwkJiYXP0bZZifGmxbh?= NYTTe4N4OTF|NUC5NVM>
PAM 212 NEToXpZIem:5dHigTY5pcWKrdHnvckBCe3OjeR?= NWXhVpRGOTByIH7N MoPXO|IhcA>? NFTYUW5FVVOR NYfMNo9iUW6qaXLpeJMh[2WubDD2bYFjcWyrdIm= MV:xNVM2ODlzMx?=
PAM-LY2 MX;Hdo94fGhiSX7obYJqfGmxbjDBd5NigQ>? Mmn2NVAxKG6P NX\WSFB6PzJiaB?= Mo\6SG1UVw>? NGTnWYNKdmirYnn0d{Bk\WyuII\pZYJqdGm2eR?= NXq5eXBzOTF|NUC5NVM>
B4B8 M2q5emdzd3e2aDDJcohq[mm2aX;uJGF{e2G7 NI\GOIoyODBibl2= M4j0Z|czKGh? MX;EUXNQ M1LpWWlvcGmkaYTzJINmdGxidnnhZoltcXS7 M3iyRlEyOzVyOUGz
B7E3 MlXvS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl? NXu0UmlQOTByIH7N MkTSO|IhcA>? NYq4PWhqTE2VTx?= NHLROYhKdmirYnn0d{Bk\WyuII\pZYJqdGm2eR?= NYP4Nnp7OTF|NUC5NVM>
UM-SCC-9 M2P5Smdzd3e2aDDJcohq[mm2aX;uJGF{e2G7 MWOxNFAhdk1? NXvNTJZRPzJiaB?= MWPEUXNQ MojwTY5pcWKrdIOgZ4VtdCC4aXHibYxqfHl? MYmxNVM2ODlzMx?=
UM-SCC-11B NEjBVnNIem:5dHigTY5pcWKrdHnvckBCe3OjeR?= M4fUcFExOCCwTR?= M3v5T|czKGh? MUDEUXNQ M3zIfWlvcGmkaYTzJINmdGxidnnhZoltcXS7 Mmn6NVE{PTB7MUO=
H460 NYmxfmluTnWwY4Tpc44hSXO|YYm= MmrWNVAh|ryP NF63O4wzPCCq NFjqOoJFVVOR NFvkeWlKdmS3Y3XzJGJkdC1{IIDoc5NxcG:{eXzheIlwdiCjbnSgZ4xm[X[jZ3WgZ49zemWuYYTl[EB4cXSqIFeyMW0heGijc3WgZZJz\XO2 MoKzNVI1QTJzMUe=
U266 NVHIUnB3T3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm= NInCNJA2ODBibnevcYw> MkTEOFghcA>? MoLwSG1UVw>? Ml\1TY5pcWKrdIOgZ4VtdCCpcn;3eIg> M2O0RlEzPjNzNkG5
ARH77 MmXLS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl? MlTUOVAxKG6pL33s MXm0PEBp MlrLSG1UVw>? NX;ifXJGUW6qaXLpeJMh[2WubDDndo94fGh? Mlz0NVI3OzF4MUm=
WAD-1 NWTUPWI{T3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm= M2Hye|UxOCCwZz;tcC=> NHWzPZQ1QCCq MXrEUXNQ MV3Jcohq[mm2czDj[YxtKGe{b4f0bC=> MX2xNlY{OTZzOR?=
U266/LR7 MWfHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>? M2LSfVUxOCCwZz;tcC=> NV3t[mN5PDhiaB?= NWfqV|d7TE2VTx?= MlzKTY5pcWKrdIOgZ4VtdCCpcn;3eIg> MVuxNlY{OTZzOR?=
U266/dox4 NWrZfWxRT3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm= M2PUU|UxOCCwZz;tcC=> NUXLZoNHPDhiaB?= NFHyUpNFVVOR M1LBe2lvcGmkaYTzJINmdGxiZ4Lve5Rp MYqxNlY{OTZzOR?=
RPMI8226/LR5 Mn\VS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl? M2LwWFUxOCCwZz;tcC=> NHHmUo81QCCq MmTOSG1UVw>? MmLPTY5pcWKrdIOgZ4VtdCCpcn;3eIg> NHHhfHUyOjZ|MU[xPS=>
H460 M{TPXGdzd3e2aDDJcohq[mm2aX;uJGF{e2G7 NHHkfWUyOCEQvF2= M2\rPFczKGh? NGLpbGdFVVOR MmPaTWM2OD1zMECgcm0> MXyxNlY{OTZ{MB?=
H358 NVTrcpNwT3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm= NYDJWmx4OTBizszN NH31epE4OiCq NF\QfZhFVVOR MWHJR|UxRTdyIH7N NIHQUFMyOjZ|MU[yNC=>
H322 M2\VTWdzd3e2aDDJcohq[mm2aX;uJGF{e2G7 MnnDNVAh|ryP NYPWT2JwPzJiaB?= Mn3uSG1UVw>? M3PWVWlEPTB;NkKwJI5O NGjYS2kyOjZ|MU[yNC=>
H460 NI\tZ2pHfW6ldHnvckBCe3OjeR?= MV2xNFAhdk1? NXn4ZZk1OjRiaB?= MmrxSG1UVw>? MXHJcoR2[2W|IFeyMW0ueGijc3WgZZJz\XO2IHHu[EB1fWK3bHnuJIF{e2WvYnz5MYRqe2G|c3XtZox6 NUfBVGpOOTJ4M{G2NlA>
LNCap-Pro5 NIrmPHBHfW6ldHnvckBCe3OjeR?= NHHIcnEyKM7:TR?= NF\1SJY1KGh? M3\MNmROW09? NYT5Xnd6W3SjYnnsbZpmeyCyNUO= MVyxOFYyOjV|Mh?=
T29 M3jjVWFxd3C2b4Ppd{BCe3OjeR?= NW[xXJRFPTBibl2= Mn\3OFghcCB? NWjrWXlUTE2VTx?= MWLJcoR2[2W|IHPlcIwh[XCxcITvd4l{ MUKxOlc4QDF5OR?=
T29Kt1 MV;BdI9xfG:|aYOgRZN{[Xl? NHrIR3U2OCCwTR?= Mn:1OFghcCB? M3\nd2ROW09? M3z5dGlv\HWlZYOgZ4VtdCCjcH;weI9{cXN? NWXsSXpMOTZ5N{ixO|k>
HCT116 MUPBdI9xfG:|aYOgRZN{[Xl? NWnSS25HPTBibl2= MnLaOFghcCB? NWLqNmxqTE2VTx?= NVXWfoxOUW6mdXPld{Bk\WyuIHHwc5B1d3Orcx?= MVuxOlc4QDF5OR?=
HKe-3 M2nGUmFxd3C2b4Ppd{BCe3OjeR?= NYTwPIdqPTBibl2= M2TzVlQ5KGhi MmWySG1UVw>? MnHSTY5lfWOnczDj[YxtKGGyb4D0c5Nqew>? MljTNVY4PzhzN{m=
NB-1691 MYTHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>? M2DBR|Eh|ryP M4DqdlczKGh? MVHJcohq[mm2czDj[YxtKHC{b3zp[oVz[XSrb36geI8hPSV? NFW3PGMyPzZ6OU[4OC=>
CHLA-255 MXLHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>? MVWxJO69VQ>? M4\IflczKGh? M4Ly[mlvcGmkaYTzJINmdGxicILvcIln\XKjdHnvckB1dyB{JR?= NYLDSo0yOTd4OEm2PFQ>
SK-N-AS NUTzSFk6T3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm= MXuxJO69VQ>? M2PPUlczKGh? MkLPTY5pcWKrdIOgZ4VtdCCycn;sbYZmemG2aX;uJJRwKDFyJR?= M4j4VlE4Pjh7Nki0
NB-1691 MWfGeY5kfGmxbjDBd5NigQ>? Mn\INVAhdk1? M2Dn[lI1KGh? Mmi2V4lodmmoaXPhcpRtgSC{ZXT1Z4V{KGOnbHzzJIlvKHSqZTDHNE9IOSCyaHHz[S=> NX;GcoI3OTd4OEm2PFQ>
CHLA-255 MWrGeY5kfGmxbjDBd5NigQ>? M2jsZVExKG6P Mn;LNlQhcA>? NGTGVWVOd2Snc4TsfUBz\WS3Y3XzJINmdGy|IHnuJJRp\SCJMD;HNUBxcGG|ZR?= MVyxO|Y5QTZ6NB?=
RPMI 8226 MV;GeY5kfGmxbjDBd5NigQ>? NFTBXIMzOCCwTR?= M4XORVghcA>? NYPmO5JJW2mpbnnmbYNidnSueTDlcohidmOnczDOSk3PwkJiYXP0bZZqfHl? NFz4[pIyQTR|NkC1NC=>
MM.1S MnzhSpVv[3Srb36gRZN{[Xl? M{PMNVIxKG6P M2rkUFghcA>? NFLJSJRUcWewaX\pZ4FvfGy7IHXubIFv[2W|IF7GMe67SiCjY4Tpeol1gQ>? MlXvNVk1OzZyNUC=
U266 M2PEWmZ2dmO2aX;uJGF{e2G7 Mlr5NlAhdk1? MUe4JIg> MY\TbYdvcW[rY3HueIx6KGWwaHHuZ4V{KE6ILd86RkBi[3Srdnn0fS=> NXyzVJVYOTl2M{[wOVA>
OPM1 NYXOT3czTnWwY4Tpc44hSXO|YYm= M{\VcFIxKG6P MkfJPEBp NH\1W3hUcWewaX\pZ4FvfGy7IHXubIFv[2W|IF7GMe67SiCjY4Tpeol1gQ>? MWKxPVQ{PjB3MB?=
INA6 NHHyPIZHfW6ldHnvckBCe3OjeR?= NHPNO3EzOCCwTR?= MXG4JIg> MXLTbYdvcW[rY3HueIx6KGWwaHHuZ4V{KE6ILd86RkBi[3Srdnn0fS=> NWr5U2R7OTl2M{[wOVA>
OPM2 NFTm[XlHfW6ldHnvckBCe3OjeR?= Mk\SNlAhdk1? M2D4ZlghcA>? MXHTbYdvcW[rY3HueIx6KGWwaHHuZ4V{KE6ILd86RkBi[3Srdnn0fS=> NUHNXnMzOTl2M{[wOVA>
RPMI 8226 NYnzVmxsTnWwY4Tpc44hSXO|YYm= NEfaemUzOCCwTR?= MYW4JIg> MYXJcoR2[2W|IFTORUB{gW62aHXzbZM> NYDCcGN3OTl2M{[wOVA>
BaF/3 NHjOVVlIem:5dHigTY5pcWKrdHnvckBCe3OjeR?= NVPoe2FXOTByIH7N MlHzOFghcA>? M4TodGlEPTB;Nj6yJI5O M2rlcFIxOzB3Nkmy
BaF/3-p210 NGXjPYxIem:5dHigTY5pcWKrdHnvckBCe3OjeR?= NVXHNGx1OTByIH7N NVX4RnY5PDhiaB?= MlHQTWM2OD12Lkegcm0> MX:yNFMxPTZ7Mh?=
TCC-S NXX4O|M5T3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm= MUSxNFAhdk1? MmjFOFghcA>? MYXJR|UxRTJwODDuUS=> MlPkNlA{ODV4OUK=
BaF/3 NVPXOlZvTnWwY4Tpc44hSXO|YYm= MUO2JI5O NX;GU2QxPDhiaB?= NFTScFVKdmS3Y3XzJIEh\3KnYYSgS|Eh[2WubD3jfYNt\SCjcoLld5Q> NWHrWmR[OjB|MEW2PVI>
BaF/3-p210 MlvmSpVv[3Srb36gRZN{[Xl? NYDK[GVzPiCwTR?= M3K2blQ5KGh? NVjlTHVsUW6mdXPld{BiKHOuaXfoeEBIOSClZXzsMYN6[2ynIHHydoV{fA>? M{\4RlIxOzB3Nkmy
BaF/3-p210 NWPWcGVuTnWwY4Tpc44hSXO|YYm= MXq2JI5O M{DodFI1KGh? NW\2R4lvWmWmdXPld{B1cGVicHjvd5Bpd3K7bHH0bY9vKGGwZDD0bIUh[WO2aY\peJkhd2ZiUnK= NYXPWlZLOjB|MEW2PVI>
Raji MUPHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>? NX6xWpl3OSEQvF2= M{nrNFI1KGh? NGjrXG5T\WS3Y3XzJINmdGxidnnhZoltcXS7wrC= NWG3XIF5OjFzN{C5PFg>
LCL-1 M37KV2dzd3e2aDDJcohq[mm2aX;uJGF{e2G7 M1vHZlEh|ryP NIK4Zm4zPCCq NFjjOVNT\WS3Y3XzJINmdGxidnnhZoltcXS7wrC= NVi4R3JxOjFzN{C5PFg>
LCL-2 NVT0TlVIT3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm= MVixJO69VQ>? Ml3DNlQhcA>? NFXvVm1T\WS3Y3XzJINmdGxidnnhZoltcXS7wrC= MkTaNlEyPzB7OEi=
BJAB NV\0XXBoT3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm= NWj0PWZ5OSEQvF2= Mn\JNlQhcA>? M4rubXJm\HWlZYOgZ4VtdCC4aXHibYxqfHoEoB?= MnvQNlEyPzB7OEi=
SNT-13 M37m[Wdzd3e2aDDJcohq[mm2aX;uJGF{e2G7 NWXQR45XOSEQvF2= NWL6enRxOjRiaB?= MkPLVoVlfWOnczDj[YxtKH[rYXLpcIl1gcLi NYW1cJREOjFzN{C5PFg>
SNT-16 MorIS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl? MnfLNUDPxE1? NVHpfIpSOjRiaB?= MVrS[YR2[2W|IHPlcIwhfmmjYnnsbZR6yqB? M3LKblIyOTdyOUi4
Jurkat NV;MZXBvT3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm= MlG3NUDPxE1? NXj3RoxVOjRiaB?= NInYPZdT\WS3Y3XzJINmdGxidnnhZoltcXS7wrC= MWKyNVE4ODl6OB?=
KAI-3 MXjHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>? M2j0ZlEh|ryP NUn4fXZPOjRiaB?= NVnj[3NNWmWmdXPld{Bk\WyuII\pZYJqdGm2edMg M3rxOFIyOTdyOUi4
SNK-6 NGXNO21Iem:5dHigTY5pcWKrdHnvckBCe3OjeR?= NYTtdnFbOSEQvF2= MVKyOEBp NF;BUo5T\WS3Y3XzJINmdGxidnnhZoltcXS7wrC= MVSyNVE4ODl6OB?=
KHYG-1 NWnXXmJOT3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm= MnLDNUDPxE1? MWmyOEBp NGW4d|FT\WS3Y3XzJINmdGxidnnhZoltcXS7wrC= MYCyNVE4ODl6OB?=
SNT-16 NXvOWmJ4SXCxcITvd4l{KEG|c3H5 NVT5UG16OSEQvF2= MnzlOkBp NHjzbFFKdmS3Y3XzJINmdGxiYYDvdJRwe2m| MVGyNVE4ODl6OB?=
Jurkat MkfjRZBweHSxc3nzJGF{e2G7 MUOxJO69VQ>? NX\aU5pxPiCq NFnHZ3lKdmS3Y3XzJINmdGxiYYDvdJRwe2m| MmfKNlEyPzB7OEi=
KAI-3 NVvCfJZPSXCxcITvd4l{KEG|c3H5 NV3HNmJ4OSEQvF2= Mle0OkBp MV\JcoR2[2W|IHPlcIwh[XCxcITvd4l{ NWHNUXBHOjFzN{C5PFg>
KHYG-1 M4[0[2Fxd3C2b4Ppd{BCe3OjeR?= M1ix[lEh|ryP MXy2JIg> NYPpeZYyUW6mdXPld{Bk\WyuIHHwc5B1d3Orcx?= NE\oXJkzOTF5MEm4PC=>
SNT-13 MXnBcpRqfmm{YXygRZN{[Xl? M1:2NlEh|ryP NIf6U5QzPCCq M4XHPGlv\HWlZYOgcJl1cWNiaX7m[YN1cW:wIH;mJGVDXg>? MXeyNVE4ODl6OB?=
SNT-16 NVj0fJpHSW62aY\pdoFtKEG|c3H5 M3TDVVEh|ryP M2nhclI1KGh? NYC0RnZkUW6mdXPld{BtgXSrYzDpcoZm[3Srb36gc4YhTUKY MWKyNVE4ODl6OB?=
KAI-3 MY\BcpRqfmm{YXygRZN{[Xl? MWqxJO69VQ>? M3vld|I1KGh? NGXFU|FKdmS3Y3XzJIx6fGmlIHnu[oVkfGmxbjDv[kBGSlZ? NFjrV5gzOTF5MEm4PC=>
SNK-6 NVPSc2lISW62aY\pdoFtKEG|c3H5 M1nmZ|Eh|ryP NGrSWGozPCCq NYK1eJdKUW6mdXPld{BtgXSrYzDpcoZm[3Srb36gc4YhTUKY MmfONlEyPzB7OEi=
RAW 264.7 MYnHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>? M4fZT|ExOCCwTR?= MYe0PEBp NGGxN2hT\WS3Y3XzJINmdGxidnnhZoltcXS7wrC= MnTFNlI1OjdzNUS=
A375 M4jHemFxd3C2b4Ppd{BCe3OjeR?= M1rocVExKG6P NGO0OoQzPCCq MnPHTY5lfWOnczDj[YxtKGGyb4D0c5Nqew>? M4LGTVI{ODd7MEiz
BLM NV\GTos4SXCxcITvd4l{KEG|c3H5 NWfIbItxOTBibl2= MUGyOEBp NWnLPGFLUW6mdXPld{Bk\WyuIHHwc5B1d3Orcx?= NV7BSlA2OjNyN{mwPFM>
A375 NHe3bHVCfXSxcHjh[5khSXO|YYm= NULsUYlMOTBibl2= M4K1flEzKGh? NGfiVo5KdmS3Y3XzJIZwem2jdHnvckBw\iCjdYTvdIhi\2:|b33ldy=> MXiyN|A4QTB6Mx?=
BLM MlWyRZV1d3CqYXf5JGF{e2G7 MorxNVAhdk1? Mn\uNVIhcA>? NFrocZJKdmS3Y3XzJIZwem2jdHnvckBw\iCjdYTvdIhi\2:|b33ldy=> MU[yN|A4QTB6Mx?=
H1299 NHj6eWdCeG:ydH;zbZMhSXO|YYm= M3\Kc|gxKG6P MmXHNlQhcA>? M4fGcGROW09? NF:5bHFU\W6|aYTpfoV{KE6VQ1zDJINmdGy|IITvJG1USy2mZYLpeoVlKGmFOT3pcoR2[2WmIHHwc5B1d3Orcx?= MoPKNlU{OjN4OUO=
Hut-78 NF;G[ZNHfW6ldHnvckBCe3OjeR?= M1HzcFExOCCwTR?= M2LGOlI1KGh? NHzFdY5FVVOR MWXEc5dvemWpdXzheIV{KFSJRj5OtlEh[W6mIFnMMVExKGW6cILld5Nqd25? NXPF[nh6OjV4OEGzN|U>
H9 MlHNSpVv[3Srb36gRZN{[Xl? NXPTVVBEOTByIH7N MXKyOEBp NH7vS3JFVVOR MmL5SI94dnKnZ4XsZZRmeyCWR1[t{tIyKGGwZDDJUE0yOSCneIDy[ZN{cW:w M{\JXVI2PjhzM{O1
HH NFfsb2lHfW6ldHnvckBCe3OjeR?= MlPmNVAxKG6P NGTQeZIzPCCq MnfBSG1UVw>? NH\N[nJld3ewcnXneYxifGW|IGTHSk3PujFiYX7kJGlNNTF{IHX4dJJme3Orb36= NV3RVWtrOjV4OEGzN|U>
Hut-78 NV:0[ZV6VWmpcnH0bY9vKEG|c3H5 NE\JOGUyODBibl2= M4HpfVI1KGh? NYW4Omt5TE2VTx?= NILTR29T\WS3Y3XzJINmdGxibXnndoF1cW:wIHL5JFgx6oDVOUCl M{XkUVI2PjhzM{O1
HH NEjKcmVOcWe{YYTpc44hSXO|YYm= M3LzRVExOCCwTR?= M{PHSFI1KGh? M3vOOWROW09? MnXZVoVlfWOnczDj[YxtKG2rZ4LheIlwdiCkeTC4NQKBmzlzJR?= NXPUNJA2OjV4OEGzN|U>
U937 NWr1V2d7TnWwY4Tpc44hSXO|YYm= NXLXdGsxOTByIH7N NUGz[|M1PiCq MkXqTY5lfWOnczDJUE05KGW6cILld5Nqd25iaX6gUHBUNXO2aX31cIF1\WRiVUmzO{Bu[WO{b4DoZYdmew>? MlW1NlU4QTF2N{e=
human PBMC MoPvSpVv[3Srb36gRZN{[Xl? MU[xNFAhdk1? NFPOdlEzPCCq NFm4OJZKdmS3Y3XzJGlNNThicnXs[YF{\Q>? Moe4NlU4QTF2N{e=
ES6 MUHHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>? M{LTXmlEPTB;MD6wNFIyKG6P MWDTRW5ITVJ?
SK-UT-1 MkmyS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl? MkD4TWM2OD1yLkG2N{BvVQ>? M3jy[3NCVkeHUh?=
SH-4 M2HuNmdzd3e2aDDJcohq[mm2aX;uJGF{e2G7 M{PFOWlEPTB;MD6xO|Mhdk1? NUPCOZlIW0GQR1XS
TE-9 M3;aN2dzd3e2aDDJcohq[mm2aX;uJGF{e2G7 NYfPZphPUUN3ME2wMlE5OiCwTR?= NXr6fJVrW0GQR1XS
A253 NHG3PXlIem:5dHigTY5pcWKrdHnvckBCe3OjeR?= MXnJR|UxRTBwMkC4JI5O MkXsV2FPT0WU
no-10 NHTRcpRIem:5dHigTY5pcWKrdHnvckBCe3OjeR?= MkjGTWM2OD1yLkKxJI5O NHPlXo5USU6JRWK=
MMAC-SF NHLaWFRIem:5dHigTY5pcWKrdHnvckBCe3OjeR?= MkWyTWM2OD1yLkKxOkBvVQ>? NV;PXXJkW0GQR1XS
A101D NGC4UVlIem:5dHigTY5pcWKrdHnvckBCe3OjeR?= Mlm5TWM2OD1yLkKyOUBvVQ>? NVznOJd2W0GQR1XS
NTERA-S-cl-D1 M2XQZWdzd3e2aDDJcohq[mm2aX;uJGF{e2G7 MoC5TWM2OD1yLkK0N{BvVQ>? M1vxTXNCVkeHUh?=
8-MG-BA NFSxPGdIem:5dHigTY5pcWKrdHnvckBCe3OjeR?= NIHHVo5KSzVyPUCuNlUhdk1? Ml7OV2FPT0WU
KNS-42 NVL6NpZET3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm= MYHJR|UxRTBwMkW4JI5O NFfjVodUSU6JRWK=
LXF-289 M3XyS2dzd3e2aDDJcohq[mm2aX;uJGF{e2G7 NFzCUWVKSzVyPUCuNlY6KG6P MVvTRW5ITVJ?
OVCAR-4 Mn75S5Jwf3SqIFnubIljcXSrb36gRZN{[Xl? MUfJR|UxRTBwMki5JI5O MVjTRW5ITVJ?
LOUCY Mke1S5Jwf3SqIFnubIljcXSrb36gRZN{[Xl? NWe4eJRUUUN3ME2wMlI6OyCwTR?= MkTFV2FPT0WU
BB65-RCC MmnJS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl? NF3xbINKSzVyPUCuN|A1KG6P MXPTRW5ITVJ?
D-542MG NELFNoVIem:5dHigTY5pcWKrdHnvckBCe3OjeR?= MUTJR|UxRTBwM{K5JI5O M33zenNCVkeHUh?=
ONS-76 NWLp[pNCT3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm= MU\JR|UxRTBwM{Ogcm0> MmDZV2FPT0WU
BB30-HNC NITkOlhIem:5dHigTY5pcWKrdHnvckBCe3OjeR?= NVLyO5RqUUN3ME2wMlM{PSCwTR?= MXnTRW5ITVJ?
KS-1 MYjHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>? NXXVc44{UUN3ME2wMlM1KG6P NWGyZmJVW0GQR1XS
A388 NH\EVldIem:5dHigTY5pcWKrdHnvckBCe3OjeR?= M4fnPGlEPTB;MD6zOVYhdk1? M3K0PHNCVkeHUh?=
ES8 MYTHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>? MXLJR|UxRTBwNDDuUS=> M2XMVnNCVkeHUh?=
MZ2-MEL MXzHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>? M13XZ2lEPTB;MD60NFchdk1? NFHjdVlUSU6JRWK=
HCC2998 M2P1U2dzd3e2aDDJcohq[mm2aX;uJGF{e2G7 MVLJR|UxRTBwNEGyJI5O MVzTRW5ITVJ?
D-247MG MmT2S5Jwf3SqIFnubIljcXSrb36gRZN{[Xl? Mk\QTWM2OD1yLkSxN{BvVQ>? NFfObXZUSU6JRWK=
ACN NWPMTGZrT3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm= NVfpZZNmUUN3ME2wMlQyPyCwTR?= Mk[xV2FPT0WU
LB2518-MEL MUjHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>? MlPvTWM2OD1yLkSyOUBvVQ>? NHfaRYxUSU6JRWK=
ES1 MlPpS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl? M1q3OGlEPTB;MD60N{BvVQ>? MlToV2FPT0WU
HCE-T NUPMbFBpT3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm= NGnIeW1KSzVyPUCuOFM6KG6P MV\TRW5ITVJ?
OS-RC-2 MoTMS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl? NFr6dJhKSzVyPUCuOFQhdk1? NXf4dnpqW0GQR1XS
MFH-ino M3;6Wmdzd3e2aDDJcohq[mm2aX;uJGF{e2G7 MXXJR|UxRTBwNESzJI5O NWrv[2drW0GQR1XS
OCUB-M MnezS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl? Ml7rTWM2OD1yLkS0O{BvVQ>? NV;xfFJtW0GQR1XS
CP66-MEL NEX5c4lIem:5dHigTY5pcWKrdHnvckBCe3OjeR?= Moj5TWM2OD1yLkS3N{BvVQ>? NVj2fJZkW0GQR1XS
LB771-HNC NYXFc3BlT3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm= MXrJR|UxRTBwNEe0JI5O NFXxdlNUSU6JRWK=
DSH1 Mk\ZS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl? NGDDOYdKSzVyPUCuOFghdk1? NIW0[lRUSU6JRWK=
HUTU-80 NGDzV4lIem:5dHigTY5pcWKrdHnvckBCe3OjeR?= MYnJR|UxRTBwNUOzJI5O NXnGUXBWW0GQR1XS
CESS MnfwS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl? NXznRVhlUUN3ME2wMlU{QCCwTR?= Mke0V2FPT0WU
NCI-H747 MlXpS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl? NYm4WmtFUUN3ME2wMlU{QSCwTR?= MUHTRW5ITVJ?
HT-144 MnHzS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl? MWHJR|UxRTBwNUe2JI5O NGPVdHdUSU6JRWK=
COLO-829 MlnaS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl? NWnESI1nUUN3ME2wMlYyPCCwTR?= MmXyV2FPT0WU
A4-Fuk NIC5Z|NIem:5dHigTY5pcWKrdHnvckBCe3OjeR?= NH3PNZJKSzVyPUCuOlI{KG6P M3Hj[HNCVkeHUh?=
GI-ME-N MYrHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>? M4\DTWlEPTB;MD62N|Qhdk1? NELSfI1USU6JRWK=
LB831-BLC MYTHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>? M3TVTGlEPTB;MD62OFEhdk1? MoPzV2FPT0WU
HOP-62 NIDHV25Iem:5dHigTY5pcWKrdHnvckBCe3OjeR?= M3HofWlEPTB;MD62OFchdk1? NVXxbYJ5W0GQR1XS
BB49-HNC NXrMb3Z7T3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm= M{PpS2lEPTB;MD62OVIhdk1? MlvPV2FPT0WU
D-336MG NVTRcnJ{T3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm= M3rCZWlEPTB;MD62OVchdk1? M2XLO3NCVkeHUh?=
TK10 NX\5dG9PT3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm= MlrLTWM2OD1yLk[3PUBvVQ>? Mlr4V2FPT0WU
Ramos-2G6-4C10 M1zGUGdzd3e2aDDJcohq[mm2aX;uJGF{e2G7 M{DDRmlEPTB;MD62PVMhdk1? MnPEV2FPT0WU
LB373-MEL-D M1LheWdzd3e2aDDJcohq[mm2aX;uJGF{e2G7 M{HBOmlEPTB;MD63JI5O MonWV2FPT0WU
SF126 M{[4eWdzd3e2aDDJcohq[mm2aX;uJGF{e2G7 MmDTTWM2OD1yLkewNUBvVQ>? NEDEXINUSU6JRWK=
UACC-257 M{LnO2dzd3e2aDDJcohq[mm2aX;uJGF{e2G7 M4C5cGlEPTB;MD63NUBvVQ>? NFr3[ZRUSU6JRWK=
KINGS-1 M{DMe2dzd3e2aDDJcohq[mm2aX;uJGF{e2G7 MWPJR|UxRTBwN{KyJI5O Ml74V2FPT0WU
LS-513 NWjUfIxQT3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm= MYjJR|UxRTBwN{O5JI5O MUDTRW5ITVJ?
GI-1 NIHwRZpIem:5dHigTY5pcWKrdHnvckBCe3OjeR?= NVy0[XNTUUN3ME2wMlc3PCCwTR?= M4PheHNCVkeHUh?=
ES7 NUXNbVJrT3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm= M3v2dGlEPTB;MD63OlYhdk1? MoPHV2FPT0WU
LB2241-RCC NXLzVIVmT3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm= MYfJR|UxRTBwOEC0JI5O M2rO[HNCVkeHUh?=
D-263MG MlTiS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl? MXnJR|UxRTBwOEC3JI5O MVzTRW5ITVJ?
SW684 MXjHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>? NYDCcI5HUUN3ME2wMlgzOSCwTR?= M17ObnNCVkeHUh?=
ML-2 MUHHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>? MlTmTWM2OD1yLkiyNUBvVQ>? M4DT[XNCVkeHUh?=
SK-LMS-1 MXzHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>? NGjzZodKSzVyPUCuPFU1KG6P NYLMOJBlW0GQR1XS
TE-5 MlfQS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl? Mn:xTWM2OD1yLki2OUBvVQ>? MUXTRW5ITVJ?
QIMR-WIL Ml\TS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl? MWXJR|UxRTBwOEi5JI5O NGnqT4tUSU6JRWK=
NCI-H1355 NYCwVpRrT3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm= M3zzUGlEPTB;MD64PVUhdk1? M1W4TnNCVkeHUh?=
SNB75 NWG1b3JbT3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm= NILRW3VKSzVyPUCuPVEzKG6P NGLqUFhUSU6JRWK=
RXF393 NEPReW9Iem:5dHigTY5pcWKrdHnvckBCe3OjeR?= MmXMTWM2OD1yLkmxOEBvVQ>? MWrTRW5ITVJ?
IST-MEL1 MkDpS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl? MVHJR|UxRTBwOUG3JI5O NV7rVXFCW0GQR1XS
SF268 NH7LV21Iem:5dHigTY5pcWKrdHnvckBCe3OjeR?= MXzJR|UxRTBwOUKzJI5O NIjWZW1USU6JRWK=
KALS-1 MXrHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>? M17xWWlEPTB;MD65NlUhdk1? MXPTRW5ITVJ?
HC-1 MYfHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>? M2PqOWlEPTB;MD65O|Uhdk1? MorOV2FPT0WU
SW872 M4r2PGdzd3e2aDDJcohq[mm2aX;uJGF{e2G7 NU\aeZVyUUN3ME2wMlk6PiCwTR?= NGjMcGFUSU6JRWK=
PSN1 M4HtWGdzd3e2aDDJcohq[mm2aX;uJGF{e2G7 NHrVPI9KSzVyPUGuNFEhdk1? NYDzXI1qW0GQR1XS
TE-1 M4XLOmdzd3e2aDDJcohq[mm2aX;uJGF{e2G7 M3S1VGlEPTB;MT6wN{BvVQ>? MorjV2FPT0WU
TE-10 NVT6WIhNT3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm= MnP1TWM2OD1zLkCzJI5O NY\adZJvW0GQR1XS
RKO M{PUWWdzd3e2aDDJcohq[mm2aX;uJGF{e2G7 M2jyV2lEPTB;MT6wOkBvVQ>? NX;1VoMzW0GQR1XS
LC-2-ad MUTHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>? MmS4TWM2OD1zLkC4JI5O NYHXcXU6W0GQR1XS
SK-MM-2 NIXu[YZIem:5dHigTY5pcWKrdHnvckBCe3OjeR?= M1y2WWlEPTB;MT6wPUBvVQ>? M1fUPXNCVkeHUh?=
VA-ES-BJ NILLUZVIem:5dHigTY5pcWKrdHnvckBCe3OjeR?= NV7Pb29SUUN3ME2xMlA6KG6P NF3TOGlUSU6JRWK=
MZ7-mel NXizcIVrT3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm= NYPQcVRUUUN3ME2xMlA6KG6P NFjYeXlUSU6JRWK=
D-392MG MoX3S5Jwf3SqIFnubIljcXSrb36gRZN{[Xl? NIf3TnlKSzVyPUGuNUBvVQ>? M3jwfXNCVkeHUh?=
CCRF-CEM NXzaWFU3T3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm= M1TVeGlEPTB;MT6xN{BvVQ>? NFu3d5JUSU6JRWK=
EM-2 MmH1S5Jwf3SqIFnubIljcXSrb36gRZN{[Xl? NIL4[WNKSzVyPUGuNVYhdk1? NYPnO2Z{W0GQR1XS
HAL-01 MkPGS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl? MlnhTWM2OD1zLkG4JI5O MWHTRW5ITVJ?
TE-8 NIqz[GFIem:5dHigTY5pcWKrdHnvckBCe3OjeR?= NIfSRndKSzVyPUGuNVkhdk1? MXXTRW5ITVJ?
NCI-H1882 NH64W3hIem:5dHigTY5pcWKrdHnvckBCe3OjeR?= MVXJR|UxRTFwMjDuUS=> NVT2O2NSW0GQR1XS
Daudi M2TNOGdzd3e2aDDJcohq[mm2aX;uJGF{e2G7 NVu3PJI4UUN3ME2xMlIzKG6P NV7Re5ZGW0GQR1XS
BL-41 MYHHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>? MX7JR|UxRTFwMkWgcm0> M{HyWXNCVkeHUh?=
SR Ml34S5Jwf3SqIFnubIljcXSrb36gRZN{[Xl? MoDkTWM2OD1zLkK1JI5O NFPkNVFUSU6JRWK=
KM12 MUfHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>? NEXIVHhKSzVyPUGuNlchdk1? M4rlbnNCVkeHUh?=
K5 MXfHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>? MX3JR|UxRTFwMkigcm0> M1v0bnNCVkeHUh?=
A3-KAW NFP3fJRIem:5dHigTY5pcWKrdHnvckBCe3OjeR?= NVy4fpZPUUN3ME2xMlI5KG6P Ml\IV2FPT0WU
CMK MkDHS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl? NH;tPHZKSzVyPUGuNlkhdk1? NEPxSGRUSU6JRWK=
Calu-6 NGjBXoFIem:5dHigTY5pcWKrdHnvckBCe3OjeR?= M3nhcmlEPTB;MT6yPUBvVQ>? NHTjc3JUSU6JRWK=
IST-SL2 MkPoS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl? NGeyd|lKSzVyPUGuN|Ehdk1? NH;repBUSU6JRWK=
OPM-2 MnjmS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl? NVfJSVZLUUN3ME2xMlM{KG6P NVezT|VEW0GQR1XS
DU-4475 MVHHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>? NVrDPHBKUUN3ME2xMlM3KG6P M2W3ZnNCVkeHUh?=
ECC12 M3fSUmdzd3e2aDDJcohq[mm2aX;uJGF{e2G7 NIfKdFRKSzVyPUGuN|chdk1? M{XhZnNCVkeHUh?=
L-540 MVrHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>? NV23cYtoUUN3ME2xMlM4KG6P MWPTRW5ITVJ?
CAS-1 M4DqN2dzd3e2aDDJcohq[mm2aX;uJGF{e2G7 MYPJR|UxRTFwM{egcm0> NE\I[JNUSU6JRWK=
PF-382 NIXtbnZIem:5dHigTY5pcWKrdHnvckBCe3OjeR?= MkDMTWM2OD1zLkS3JI5O NH7xe25USU6JRWK=
LS-411N MkfKS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl? M2flXWlEPTB;MT61N{BvVQ>? M1TpZXNCVkeHUh?=
NCI-H69 NHnP[2RIem:5dHigTY5pcWKrdHnvckBCe3OjeR?= Mo\iTWM2OD1zLkW0JI5O M2XrWnNCVkeHUh?=
NB12 Mn31S5Jwf3SqIFnubIljcXSrb36gRZN{[Xl? Ml7DTWM2OD1zLkW2JI5O NIDMV2NUSU6JRWK=
HEL NXOwbWR2T3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm= Mn74TWM2OD1zLk[xJI5O Mnm5V2FPT0WU
GCIY MoLQS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl? M3rHNGlEPTB;MT62NkBvVQ>? NGTkcYZUSU6JRWK=
EHEB NHLNRVNIem:5dHigTY5pcWKrdHnvckBCe3OjeR?= Mo[xTWM2OD1zLk[3JI5O NXv0eHozW0GQR1XS
TGBC1TKB MYDHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>? NGLCc2ZKSzVyPUGuO|Ehdk1? NIT1S|BUSU6JRWK=
KURAMOCHI M{j0Rmdzd3e2aDDJcohq[mm2aX;uJGF{e2G7 MXfJR|UxRTFwN{Kgcm0> NUDtXHd3W0GQR1XS
U-266 M1XLc2dzd3e2aDDJcohq[mm2aX;uJGF{e2G7 MUPJR|UxRTFwN{[gcm0> NETFOXdUSU6JRWK=
LC4-1 MVTHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>? MlTWTWM2OD1zLke5JI5O NIG1XGVUSU6JRWK=
NCI-H2126 MW\Hdo94fGhiSX7obYJqfGmxbjDBd5NigQ>? MmfmTWM2OD1zLkigcm0> MVnTRW5ITVJ?
NCI-H1092 MYXHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>? M33pTmlEPTB;MT64JI5O NVezWXJEW0GQR1XS
GB-1 NFXsd2RIem:5dHigTY5pcWKrdHnvckBCe3OjeR?= MX7JR|UxRTFwOEGgcm0> NWPDfFJWW0GQR1XS
MV-4-11 MUDHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>? M4[zWmlEPTB;MT64NkBvVQ>? MYDTRW5ITVJ?
Becker NWDQ[GNnT3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm= MnTSTWM2OD1zLkizJI5O M4P6eXNCVkeHUh?=
MPP-89 NFjaN4RIem:5dHigTY5pcWKrdHnvckBCe3OjeR?= NWHG[XJQUUN3ME2xMlg6KG6P NG[xN4VUSU6JRWK=
BE-13 MoDnS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl? NXvtZphMUUN3ME2xMlk{KG6P MWDTRW5ITVJ?
697 MlPQS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl? NYLaRWJsUUN3ME2xMlk6KG6P MUTTRW5ITVJ?
NKM-1 M4SwOmdzd3e2aDDJcohq[mm2aX;uJGF{e2G7 MmTsTWM2OD1{IH7N NUnIcXBiW0GQR1XS
NB13 NXfr[mdXT3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm= MYHJR|UxRTJibl2= MoX1V2FPT0WU
LS-123 M2\ibWdzd3e2aDDJcohq[mm2aX;uJGF{e2G7 NWXM[|lpUUN3ME2yMlAzKG6P NXj4[VFWW0GQR1XS
NB17 MUXHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>? NXjxVHJZUUN3ME2yMlA1KG6P NHfhUotUSU6JRWK=
LAN-6 MoDCS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl? MXrJR|UxRTJwMEWgcm0> M{P5[nNCVkeHUh?=
EW-24 M2LEfGdzd3e2aDDJcohq[mm2aX;uJGF{e2G7 NYfZSHN[UUN3ME2yMlA5KG6P NIHHVYVUSU6JRWK=
NOS-1 NVnmW2kyT3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm= MYPJR|UxRTJwMUGgcm0> M3y1UXNCVkeHUh?=
BL-70 MlnSS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl? NHn4RYtKSzVyPUKuNVIhdk1? M1WwWHNCVkeHUh?=
GT3TKB M3jKS2dzd3e2aDDJcohq[mm2aX;uJGF{e2G7 M2HJfGlEPTB;Mj6xNkBvVQ>? NVqyUYJHW0GQR1XS
HH NVPzXJhyT3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm= MmfLTWM2OD1{LkGzJI5O Mn7yV2FPT0WU
KE-37 M4fLN2dzd3e2aDDJcohq[mm2aX;uJGF{e2G7 NGHGV|BKSzVyPUKuNVMhdk1? NIfLOpdUSU6JRWK=
MOLT-4 NHfZd5pIem:5dHigTY5pcWKrdHnvckBCe3OjeR?= NFXreFBKSzVyPUKuNVMhdk1? MVfTRW5ITVJ?
EKVX M{X6TWdzd3e2aDDJcohq[mm2aX;uJGF{e2G7 MY\JR|UxRTJwMUSgcm0> M1XNfnNCVkeHUh?=
KGN NF:yfYFIem:5dHigTY5pcWKrdHnvckBCe3OjeR?= NEj3U2lKSzVyPUKuNVUhdk1? M1nrOnNCVkeHUh?=
ES4 MnvIS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl? M2D4UmlEPTB;Mj6xOkBvVQ>? Mke4V2FPT0WU
SJSA-1 M3faW2dzd3e2aDDJcohq[mm2aX;uJGF{e2G7 Mnm3TWM2OD1{LkKxJI5O M4DBdHNCVkeHUh?=
KMOE-2 MWrHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>? MnP1TWM2OD1{LkKzJI5O NFPnfZFUSU6JRWK=
NB5 M4jm[Wdzd3e2aDDJcohq[mm2aX;uJGF{e2G7 MoTiTWM2OD1{LkK3JI5O NFzaPIFUSU6JRWK=
BC-1 MWPHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>? MUnJR|UxRTJwM{Ggcm0> MV;TRW5ITVJ?
NB10 M{LDcGdzd3e2aDDJcohq[mm2aX;uJGF{e2G7 Ml3yTWM2OD1{LkOyJI5O MmfUV2FPT0WU
RPMI-8226 MV\Hdo94fGhiSX7obYJqfGmxbjDBd5NigQ>? MlvHTWM2OD1{LkO1JI5O MXPTRW5ITVJ?
SCC-3 NYPWdGR[T3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm= NWPuZZdNUUN3ME2yMlM4KG6P M3GwUnNCVkeHUh?=
ARH-77 M2TiZWdzd3e2aDDJcohq[mm2aX;uJGF{e2G7 NFXxPXpKSzVyPUKuN|ghdk1? MYTTRW5ITVJ?
NCI-H748 NF6zXG5Iem:5dHigTY5pcWKrdHnvckBCe3OjeR?= M3qzZWlEPTB;Mj6zPUBvVQ>? MmPPV2FPT0WU
KU812 NXvS[JdkT3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm= MYPJR|UxRTJwNEKgcm0> NG\0PYxUSU6JRWK=
NCI-H64 MVPHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>? NUW1NmpyUUN3ME2yMlQ1KG6P M4rFZnNCVkeHUh?=
NB69 NILLd4dIem:5dHigTY5pcWKrdHnvckBCe3OjeR?= M13HfWlEPTB;Mj60OkBvVQ>? NUfNW4pFW0GQR1XS
KNS-81-FD MXjHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>? NInYdJdKSzVyPUKuOFghdk1? NFHMdFdUSU6JRWK=
LB1047-RCC MY\Hdo94fGhiSX7obYJqfGmxbjDBd5NigQ>? MUfJR|UxRTJwNUegcm0> MmTPV2FPT0WU
EB-3 MlW1S5Jwf3SqIFnubIljcXSrb36gRZN{[Xl? M33aemlEPTB;Mj62OkBvVQ>? NHnsfFVUSU6JRWK=
Mo-T NFvLeHpIem:5dHigTY5pcWKrdHnvckBCe3OjeR?= NILKO2pKSzVyPUKuO|Qhdk1? NGniUIZUSU6JRWK=
EW-16 NYXyOZNnT3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm= MUDJR|UxRTJwN{Wgcm0> MX;TRW5ITVJ?
CTV-1 Mn;jS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl? M1LEOWlEPTB;Mj64JI5O NGrSZYFUSU6JRWK=
ETK-1 NI\pOHRIem:5dHigTY5pcWKrdHnvckBCe3OjeR?= M{\ObmlEPTB;Mj64OEBvVQ>? MlPXV2FPT0WU
C2BBe1 MV\Hdo94fGhiSX7obYJqfGmxbjDBd5NigQ>? MnP5TWM2OD1{Lki5JI5O M1nGTXNCVkeHUh?=
MOLT-16 M1\qS2dzd3e2aDDJcohq[mm2aX;uJGF{e2G7 M37KTmlEPTB;Mj64PUBvVQ>? MXnTRW5ITVJ?
SW954 NH7TZ5JIem:5dHigTY5pcWKrdHnvckBCe3OjeR?= NW\iVHBHUUN3ME2yMlkhdk1? NVi0SldbW0GQR1XS
HT MUfHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>? NWnMfo1jUUN3ME2zMlAzKG6P MkCzV2FPT0WU
KARPAS-299 NUPtcXNjT3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm= M4fqTmlEPTB;Mz6wOkBvVQ>? Mk\qV2FPT0WU
MONO-MAC-6 NXLOTo9pT3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm= MnPvTWM2OD1|LkGgcm0> Mn7TV2FPT0WU
CGTH-W-1 MWDHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>? NWTWcFFWUUN3ME2zMlEhdk1? MnnvV2FPT0WU
SK-PN-DW Mlv0S5Jwf3SqIFnubIljcXSrb36gRZN{[Xl? NEH5SVNKSzVyPUOuNVQhdk1? MYXTRW5ITVJ?
CW-2 NV7kXoxlT3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm= NYXTXWZ[UUN3ME2zMlIyKG6P MYXTRW5ITVJ?
SK-N-DZ NWXNXXh1T3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm= M3\OPGlEPTB;Mz6yOkBvVQ>? NY\lboMyW0GQR1XS
NEC8 Mn\HS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl? NFnoNmlKSzVyPUOuN|Uhdk1? NYPDeXZIW0GQR1XS
LB996-RCC MX3Hdo94fGhiSX7obYJqfGmxbjDBd5NigQ>? NH7kdHlKSzVyPUOuOEBvVQ>? MXLTRW5ITVJ?
DB MoHXS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl? NFuyRpBKSzVyPUOuOFEhdk1? MWLTRW5ITVJ?
TE-15 NGezZ2ZIem:5dHigTY5pcWKrdHnvckBCe3OjeR?= NFjCeYZKSzVyPUOuOFMhdk1? NIPJ[GhUSU6JRWK=
COR-L88 Mnm4S5Jwf3SqIFnubIljcXSrb36gRZN{[Xl? NEXL[oRKSzVyPUOuOFchdk1? NUHVXZh2W0GQR1XS
LAMA-84 M2rLe2dzd3e2aDDJcohq[mm2aX;uJGF{e2G7 MUnJR|UxRTNwNEmgcm0> MlLwV2FPT0WU
MEG-01 M1f3WWdzd3e2aDDJcohq[mm2aX;uJGF{e2G7 MX3JR|UxRTNwNEmgcm0> MX\TRW5ITVJ?
LOXIMVI NY\SZ3ExT3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm= M3O0NmlEPTB;Mz61JI5O NV;IVG9ZW0GQR1XS
RPMI-8402 NGexXFFIem:5dHigTY5pcWKrdHnvckBCe3OjeR?= MmfsTWM2OD1|LkWgcm0> M2HBRnNCVkeHUh?=
KARPAS-45 MlnMS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl? NWnTOnh{UUN3ME2zMlU1KG6P NH3re|RUSU6JRWK=
HCC1187 NEP0ZlZIem:5dHigTY5pcWKrdHnvckBCe3OjeR?= NWK3dZcxUUN3ME2zMlU1KG6P NEHZe4NUSU6JRWK=
MZ1-PC NHS4W4ZIem:5dHigTY5pcWKrdHnvckBCe3OjeR?= M2rXXGlEPTB;Mz61OEBvVQ>? MYfTRW5ITVJ?
no-11 M3zkbWdzd3e2aDDJcohq[mm2aX;uJGF{e2G7 M3;W[GlEPTB;Mz61OUBvVQ>? NHnIT5BUSU6JRWK=
EVSA-T MVrHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>? M1z2cmlEPTB;Mz62JI5O M{fOWnNCVkeHUh?=
DJM-1 M2n2emdzd3e2aDDJcohq[mm2aX;uJGF{e2G7 MVrJR|UxRTNwNkOgcm0> NYi5bJVPW0GQR1XS
COLO-684 NEHEcm5Iem:5dHigTY5pcWKrdHnvckBCe3OjeR?= NIH6dYxKSzVyPUOuOlYhdk1? NEL1ZZNUSU6JRWK=
NMC-G1 NX;BSVE2T3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm= MlfZTWM2OD1|Lk[4JI5O MUTTRW5ITVJ?
LC-1F NELCXY9Iem:5dHigTY5pcWKrdHnvckBCe3OjeR?= NXf3N3BRUUN3ME2zMlc1KG6P Ml3mV2FPT0WU
RL95-2 MV3Hdo94fGhiSX7obYJqfGmxbjDBd5NigQ>? NGHGdZZKSzVyPUOuO|khdk1? NUDKR|d7W0GQR1XS
COLO-320-HSR M4P0V2dzd3e2aDDJcohq[mm2aX;uJGF{e2G7 M3;Oe2lEPTB;Mz65NkBvVQ>? MX;TRW5ITVJ?
RCC10RGB NWn2eYpPT3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm= NHHmdnJKSzVyPUOuPVMhdk1? MonuV2FPT0WU
HD-MY-Z NHnBNppIem:5dHigTY5pcWKrdHnvckBCe3OjeR?= MVnJR|UxRTNwOUOgcm0> NFvnd2xUSU6JRWK=
NCI-H2141 NUSzPWpzT3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm= NFrHPI5KSzVyPUSuNFUhdk1? M{HIWXNCVkeHUh?=
K-562 MkDBS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl? M{Cxb2lEPTB;ND6xNkBvVQ>? NInGfllUSU6JRWK=
NCI-H1648 NVm5XHdbT3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm= M1zqS2lEPTB;ND6xN{BvVQ>? NE\pd2dUSU6JRWK=
OMC-1 Mon5S5Jwf3SqIFnubIljcXSrb36gRZN{[Xl? MmHKTWM2OD12LkG4JI5O NX;4eWREW0GQR1XS
LB647-SCLC NXXRdlNKT3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm= NGXaR4xKSzVyPUSuNlIhdk1? MojwV2FPT0WU
TE-12 NETO[VVIem:5dHigTY5pcWKrdHnvckBCe3OjeR?= NVP0RnNzUUN3ME20MlI2KG6P M2Cwb3NCVkeHUh?=
NOMO-1 M4PMdGdzd3e2aDDJcohq[mm2aX;uJGF{e2G7 M{DONGlEPTB;ND6zN{BvVQ>? NE\4cmhUSU6JRWK=
Raji M2G1NGdzd3e2aDDJcohq[mm2aX;uJGF{e2G7 MknGTWM2OD12LkS2JI5O NWXqWGxzW0GQR1XS
NALM-6 M1yzZmdzd3e2aDDJcohq[mm2aX;uJGF{e2G7 MnHGTWM2OD12LkS5JI5O M2rqU3NCVkeHUh?=
HL-60 MkXqS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl? MYDJR|UxRTRwNkegcm0> MUDTRW5ITVJ?
IST-SL1 NIHHfXNIem:5dHigTY5pcWKrdHnvckBCe3OjeR?= NHu5XoRKSzVyPUSuOlghdk1? MkHPV2FPT0WU
MHH-PREB-1 MX3Hdo94fGhiSX7obYJqfGmxbjDBd5NigQ>? MVTJR|UxRTRwOE[gcm0> MWjTRW5ITVJ?
MHH-NB-11 MoLxS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl? Mon4TWM2OD12LkmxJI5O NXjpVmhOW0GQR1XS
JiyoyeP-2003 MVfHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>? Mm\yTWM2OD13IH7N NXfHO2dGW0GQR1XS
SBC-1 M4POSGdzd3e2aDDJcohq[mm2aX;uJGF{e2G7 NIPEN2JKSzVyPUWuNFEhdk1? MV;TRW5ITVJ?
CHP-126 NEjrb49Iem:5dHigTY5pcWKrdHnvckBCe3OjeR?= NYnxRVV{UUN3ME21MlA3KG6P M1;ncnNCVkeHUh?=
LU-139 MVzHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>? NYnCcZFpUUN3ME21MlE{KG6P MVvTRW5ITVJ?
NCI-SNU-5 NXi5W|FqT3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm= MYfJR|UxRTVwMUegcm0> MUfTRW5ITVJ?
SW962 MXjHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>? Mnv0TWM2OD13LkKxJI5O NWjBN|VrW0GQR1XS
EW-1 NWjC[Y4{T3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm= MnywTWM2OD13LkOxJI5O M4nBd3NCVkeHUh?=
NCI-H1417 NWPtN4c6T3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm= M1;JV2lEPTB;NT61NUBvVQ>? M3njdHNCVkeHUh?=
LU-65 NH[zeGVIem:5dHigTY5pcWKrdHnvckBCe3OjeR?= M1v3e2lEPTB;NT64OEBvVQ>? NXX5dHFrW0GQR1XS
D-502MG NH7RPFlIem:5dHigTY5pcWKrdHnvckBCe3OjeR?= NVvuOXZxUUN3ME22MlM4KG6P NFmyZ3ZUSU6JRWK=
BC-3 NGHJb2dIem:5dHigTY5pcWKrdHnvckBCe3OjeR?= MXnJR|UxRTZwNkGgcm0> NF[3cItUSU6JRWK=
GDM-1 NHPIcmZIem:5dHigTY5pcWKrdHnvckBCe3OjeR?= M2Twc2lEPTB;Nj63O{BvVQ>? NXTQeHUzW0GQR1XS
NCI-H2196 M3THVWdzd3e2aDDJcohq[mm2aX;uJGF{e2G7 NIj5bHpKSzVyPU[uPEBvVQ>? M37DbXNCVkeHUh?=
NB1 NHrrPYtIem:5dHigTY5pcWKrdHnvckBCe3OjeR?= MVrJR|UxRTZwOEigcm0> MX\TRW5ITVJ?
NCI-H345 M3zKd2dzd3e2aDDJcohq[mm2aX;uJGF{e2G7 M{DNN2lEPTB;Nz6yJI5O NFXYdXFUSU6JRWK=
SU-DHL-1 NUG3XYRST3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm= NVT5RWtKUUN3ME23MlI1KG6P M1LGcXNCVkeHUh?=
JVM-2 M{jvVGdzd3e2aDDJcohq[mm2aX;uJGF{e2G7 NW\6OHlLUUN3ME23MlI5KG6P NHnRe2tUSU6JRWK=
LU-134-A MknyS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl? NIDDfGZKSzVyPUeuN|khdk1? MV7TRW5ITVJ?
NCI-H1694 MV7Hdo94fGhiSX7obYJqfGmxbjDBd5NigQ>? NYnXfGhmUUN3ME23MlU5KG6P MkLFV2FPT0WU
NCI-SNU-16 NFz2W5JIem:5dHigTY5pcWKrdHnvckBCe3OjeR?= MVnJR|UxRTdwNkWgcm0> MnHDV2FPT0WU
L-363 Mon3S5Jwf3SqIFnubIljcXSrb36gRZN{[Xl? Mn\kTWM2OD15Lkegcm0> MXvTRW5ITVJ?
KG-1 NHKzNGpIem:5dHigTY5pcWKrdHnvckBCe3OjeR?= NYLRWoIxUUN3ME23Mlk1KG6P NFeySZZUSU6JRWK=
MN-60 MmKwS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl? M1v0TmlEPTB;OD6xOEBvVQ>? MkLIV2FPT0WU
NB6 MoHXS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl? Mo\KTWM2OD16LkS4JI5O MYrTRW5ITVJ?
MLMA NWexe4lMT3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm= MUTJR|UxRThwOEWgcm0> M3XkcHNCVkeHUh?=
ATN-1 NEizcHNIem:5dHigTY5pcWKrdHnvckBCe3OjeR?= M2nvVmlEPTB;OD64PUBvVQ>? Mn[zV2FPT0WU
SK-NEP-1 MVTHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>? NVTud4pHUUN3ME25MlAyKG6P NYPoUpVjW0GQR1XS
DMS-114 M{jNWWdzd3e2aDDJcohq[mm2aX;uJGF{e2G7 M{X4[GlEPTB;OT62NkBvVQ>? NI\hfmlUSU6JRWK=
CTB-1 NEjNRYNIem:5dHigTY5pcWKrdHnvckBCe3OjeR?= MWHJR|UxRTlwNkegcm0> MknZV2FPT0WU
NCI-H2081 MkPQS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl? M1\x[WlEPTB;MUCuNFkhdk1? MUnTRW5ITVJ?
ES5 M{XFU2dzd3e2aDDJcohq[mm2aX;uJGF{e2G7 MljhTWM2OD1zMD6zPEBvVQ>? NXHjXJRRW0GQR1XS
HCC1599 M{jaU2dzd3e2aDDJcohq[mm2aX;uJGF{e2G7 MWTJR|UxRTFzLkmxJI5O NEO3dHNUSU6JRWK=
NCI-H23 NIfhU2NIem:5dHigTY5pcWKrdHnvckBCe3OjeR?= M2LoU2lEPTB;MUKuNVIhdk1? NEDpemRUSU6JRWK=
NCI-H1581 MmrLS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl? NHnVU5pKSzVyPUGyMlI5KG6P MY\TRW5ITVJ?
JVM-3 MXTHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>? NXLvbHBmUUN3ME2xNk46QSCwTR?= M{SxdnNCVkeHUh?=
NCI-SNU-1 M13pNGdzd3e2aDDJcohq[mm2aX;uJGF{e2G7 MUjJR|UxRTF|LkG5JI5O NYfuRXFTW0GQR1XS
NB7 NXfOeIl{T3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm= MmryTWM2OD1zNT65NkBvVQ>? MVTTRW5ITVJ?
JAR NHzmdGNIem:5dHigTY5pcWKrdHnvckBCe3OjeR?= NIHyNXlKSzVyPUG2MlE{KG6P MnLPV2FPT0WU
TGW NUXmVJZFT3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm= MnvHTWM2OD1zNj60PEBvVQ>? MYrTRW5ITVJ?
U-87-MG MknKS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl? NG\Cc2hKSzVyPUG2Mlc3KG6P NUHpRlFkW0GQR1XS
NCI-H1436 M2jEVGdzd3e2aDDJcohq[mm2aX;uJGF{e2G7 NWSzd485UUN3ME2xO{4xOSCwTR?= NUXad4t1W0GQR1XS
GOTO MnHjS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl? NFe4b2dKSzVyPUG3MlA3KG6P M3vLbnNCVkeHUh?=
COLO-800 M{HTXWdzd3e2aDDJcohq[mm2aX;uJGF{e2G7 MU\JR|UxRTF5Lk[0JI5O NIn4ZWVUSU6JRWK=
MFM-223 NIPQV5pIem:5dHigTY5pcWKrdHnvckBCe3OjeR?= MX\JR|UxRTF5LkmxJI5O NH\ySlBUSU6JRWK=
EW-18 NFXSUplIem:5dHigTY5pcWKrdHnvckBCe3OjeR?= NYjOe3lXUUN3ME2xO{46PiCwTR?= NULvXmd5W0GQR1XS
NB14 NXr0dJFUT3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm= NEXVdWRKSzVyPUG3Mlk5KG6P MXjTRW5ITVJ?
EB2 NWnOVIZYT3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm= MXHJR|UxRTF6LkC4JI5O MYHTRW5ITVJ?
EoL-1- M4TjSmdzd3e2aDDJcohq[mm2aX;uJGF{e2G7 MWfJR|UxRTF6LkOxJI5O NFO5[YZUSU6JRWK=
NCCIT MUjHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>? NH3jWXpKSzVyPUG4MlM3KG6P M2Pib3NCVkeHUh?=
DG-75 M37Demdzd3e2aDDJcohq[mm2aX;uJGF{e2G7 Moe4TWM2OD1zOD62NUBvVQ>? NEnvdm5USU6JRWK=
HCC2218 MWrHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>? MX7JR|UxRTF7LkWgcm0> M1v2TnNCVkeHUh?=
TE-6 NInU[W9Iem:5dHigTY5pcWKrdHnvckBCe3OjeR?= MWPJR|UxRTJyLkC4JI5O MXrTRW5ITVJ?
SF539 NV:yUVh4T3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm= MmjZTWM2OD1{MD62O{BvVQ>? NEfsVIhUSU6JRWK=
NCI-H446 NFnDNnZIem:5dHigTY5pcWKrdHnvckBCe3OjeR?= MXvJR|UxRTJzLkG4JI5O M3PzdHNCVkeHUh?=
IST-MES1 M1rVc2dzd3e2aDDJcohq[mm2aX;uJGF{e2G7 NHniZVNKSzVyPUKyMlc4KG6P MXfTRW5ITVJ?
NCI-H82 MYjHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>? MWDJR|UxRTJ|LkCyJI5O MY\TRW5ITVJ?
HCC2157 M4OySWdzd3e2aDDJcohq[mm2aX;uJGF{e2G7 MVrJR|UxRTJ|LkGzJI5O NGezOoRUSU6JRWK=
EW-12 NV20PHBRT3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm= NEXoSHVKSzVyPUKzMlE4KG6P NXvmV2lzW0GQR1XS
SIMA MlrmS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl? M1\Me2lEPTB;MkOuN|ghdk1? M4fK[nNCVkeHUh?=
DOHH-2 NYXRXGdoT3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm= MY\JR|UxRTJ|LkS1JI5O NGjPVHNUSU6JRWK=
IM-9 NEfINWlIem:5dHigTY5pcWKrdHnvckBCe3OjeR?= M3vhemlEPTB;MkOuOVQhdk1? MWnTRW5ITVJ?
EC-GI-10 NUO4RXBKT3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm= MWrJR|UxRTJ2LkKzJI5O NG\pcnNUSU6JRWK=
HDLM-2 MlHqS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl? MlPpTWM2OD1{ND61OEBvVQ>? NXOzN2JNW0GQR1XS
LS-1034 M4Twc2dzd3e2aDDJcohq[mm2aX;uJGF{e2G7 NWnBe2c1UUN3ME2yOU44PSCwTR?= MmrqV2FPT0WU
REH M3LD[Wdzd3e2aDDJcohq[mm2aX;uJGF{e2G7 NXzl[HRxUUN3ME2yOk41OSCwTR?= MXzTRW5ITVJ?
LU-165 M3TiSmdzd3e2aDDJcohq[mm2aX;uJGF{e2G7 MVfJR|UxRTJ4LkeyJI5O MnnvV2FPT0WU
NH-12 MnLPS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl? NIe4NopKSzVyPUK3MlY4KG6P NX76e5hKW0GQR1XS
WSU-NHL MXvHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>? NEC1XWRKSzVyPUK4MlM6KG6P NG\hTI5USU6JRWK=
ECC4 NYXmZm91T3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm= NEDSdGlKSzVyPUK4Mlc6KG6P MnjpV2FPT0WU
OCI-AML2 M1X0TGdzd3e2aDDJcohq[mm2aX;uJGF{e2G7 NXnadm9KUUN3ME2yPU43QSCwTR?= MXPTRW5ITVJ?
EW-3 NUjNRmtWT3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm= MWHJR|UxRTNyLkW5JI5O NXTGW3dxW0GQR1XS
NCI-H526 NVriNJJ3T3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm= MljJTWM2OD1|Mj61OEBvVQ>? NWnoNYhoW0GQR1XS
NCI-H719 MXfHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>? NWG3RZhnUUN3ME2zOE4{OSCwTR?= NGG4cXRUSU6JRWK=
KARPAS-422 M2jJOmdzd3e2aDDJcohq[mm2aX;uJGF{e2G7 M2jRNmlEPTB;M{WuNFQhdk1? Mn70V2FPT0WU
SK-MEL-1 M3iyTWdzd3e2aDDJcohq[mm2aX;uJGF{e2G7 MX3JR|UxRTN3LkG3JI5O MYHTRW5ITVJ?
ES3 NWPYZnRsT3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm= NVG2XIxGUUN3ME2zOU4yQSCwTR?= NGL2dmdUSU6JRWK=
UACC-812 NHPJZolIem:5dHigTY5pcWKrdHnvckBCe3OjeR?= NF\mSWZKSzVyPUO1MlQ1KG6P MXHTRW5ITVJ?
C8166 NX:0WnNlT3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm= NXzTN4JwUUN3ME2zOU44KG6P NGfidllUSU6JRWK=
MDA-MB-134-VI MXTHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>? MWfJR|UxRTN3Lki3JI5O NIr2WZJUSU6JRWK=
D-283MED MX7Hdo94fGhiSX7obYJqfGmxbjDBd5NigQ>? MnXlTWM2OD1|Nz63PUBvVQ>? MY\TRW5ITVJ?
SHP-77 NVv3RllYT3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm= M4noc2lEPTB;M{iuNFMhdk1? Mnr4V2FPT0WU
NCI-H2227 M3TlVmdzd3e2aDDJcohq[mm2aX;uJGF{e2G7 NYrt[IFnUUN3ME20NE41QSCwTR?= MkPuV2FPT0WU
SKM-1 NHTYRpNIem:5dHigTY5pcWKrdHnvckBCe3OjeR?= M2jIVWlEPTB;NEKuOlMhdk1? M2XlenNCVkeHUh?=
L-428 M4rY[Gdzd3e2aDDJcohq[mm2aX;uJGF{e2G7 MULJR|UxRTR|Lki2JI5O M3HUfHNCVkeHUh?=
RPMI-6666 M2DQT2dzd3e2aDDJcohq[mm2aX;uJGF{e2G7 MYXJR|UxRTR3Lki5JI5O Mkf0V2FPT0WU
NCI-H716 NXWwW5B1T3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm= M4PLbmlEPTB;NEiuPFEhdk1? NYrHXHBoW0GQR1XS
DMS-79 MlTSS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl? NID3PIpKSzVyPUWwMlcyKG6P NHrLWVhUSU6JRWK=
RS4-11 MYTHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>? MoTqTWM2OD13MD64PEBvVQ>? NG\MXGRUSU6JRWK=
NCI-H720 MVfHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>? NGfYVG5KSzVyPUWxMlEyKG6P MV\TRW5ITVJ?
MC-CAR NHr5b4dIem:5dHigTY5pcWKrdHnvckBCe3OjeR?= NF;nXYFKSzVyPUWxMlUzKG6P M4rrTXNCVkeHUh?=
TALL-1 M3vremdzd3e2aDDJcohq[mm2aX;uJGF{e2G7 M2nUWWlEPTB;NUOuPVEhdk1? MoHhV2FPT0WU
NCI-N87 MXXHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>? NH7i[pNKSzVyPUW0MlE5KG6P NI\TTHVUSU6JRWK=
P30-OHK MWDHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>? NXnEXYJZUUN3ME21OE43OSCwTR?= M{HEXXNCVkeHUh?=
LP-1 MoXqS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl? MnnUTWM2OD14MT6yPEBvVQ>? NHraOZlUSU6JRWK=
YT NX\CVYg1T3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm= NVThfmNWUUN3ME22NU45KG6P NUfpOmx3W0GQR1XS
MRK-nu-1 NEXRb3pIem:5dHigTY5pcWKrdHnvckBCe3OjeR?= MlPSTWM2OD14MT64NkBvVQ>? NHKybpBUSU6JRWK=
BT-474 Mke5S5Jwf3SqIFnubIljcXSrb36gRZN{[Xl? MlPMTWM2OD14NTDuUS=> NIfDW3FUSU6JRWK=
NCI-H322M MUPHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>? MV7JR|UxRTZ4LkGxJI5O MUfTRW5ITVJ?
NCI-H128 NHPpe4NIem:5dHigTY5pcWKrdHnvckBCe3OjeR?= NUDlXo04UUN3ME23OE44PyCwTR?= M2GzW3NCVkeHUh?=
KMS-12-PE NV;Q[HQ2T3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm= MYPJR|UxRTd4LkK0JI5O NWjldWQ4W0GQR1XS
KP-N-YS M37sZ2dzd3e2aDDJcohq[mm2aX;uJGF{e2G7 MYPJR|UxRTd4Lke0JI5O MkO1V2FPT0WU
ALL-PO MVPHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>? NF75WVZKSzVyPUe3MlY3KG6P M1T0SXNCVkeHUh?=
EW-13 M3S2WGdzd3e2aDDJcohq[mm2aX;uJGF{e2G7 NFv0XXdKSzVyPUe3Mlc3KG6P NWjnZ2NKW0GQR1XS
EW-11 M1[3U2dzd3e2aDDJcohq[mm2aX;uJGF{e2G7 M4rUVmlEPTB;N{iuOVIhdk1? NXr0PIV7W0GQR1XS
SK-N-FI NXLDTXM5T3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm= NYLCR|d5UUN3ME24NE4zKG6P M4iwV3NCVkeHUh?=
CAL-148 NFPOTldIem:5dHigTY5pcWKrdHnvckBCe3OjeR?= MVjJR|UxRThzLki0JI5O NUfldWdIW0GQR1XS
RL MljGS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl? M4jJ[mlEPTB;OE[uNFkhdk1? NVvw[3RSW0GQR1XS
AM-38 MlW0S5Jwf3SqIFnubIljcXSrb36gRZN{[Xl? M3jlemlEPTB;OEiuNFghdk1? NFf0TJJUSU6JRWK=
RH-1 NVXrTVRET3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm= MojyTWM2OD17OT64OUBvVQ>? MoCxV2FPT0WU
NCI-H1770 MXfHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>? MYjJR|UxRTFyMj60PUBvVQ>? NVz0XmtYW0GQR1XS
SIG-M5 MkjoS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl? MknQTWM2OD1zMEWuNFYhdk1? NVTXdm1sW0GQR1XS
GR-ST NVvscopZT3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm= Mm[4TWM2OD1zMUOuN|Qhdk1? NEO2dHFUSU6JRWK=
ST486 MlHoS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl? NV;EeVEzUUN3ME2xNVQvODZibl2= MnnSV2FPT0WU
NCI-H1650 MnHMS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl? NE\BXI9KSzVyPUGxOU4zQSCwTR?= MoDBV2FPT0WU
MHH-CALL-2 M2WyZWdzd3e2aDDJcohq[mm2aX;uJGF{e2G7 NInhRllKSzVyPUGxOU44KG6P M3\hU3NCVkeHUh?=
BV-173 NXftc3ZbT3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm= MVfJR|UxRTF{Mj63NUBvVQ>? NVLSZWNKW0GQR1XS
MC116 MXTHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>? MoO3TWM2OD1zNEiuPFUhdk1? MlPrV2FPT0WU
NCI-H524 Mk\aS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl? MWLJR|UxRTF3OT6xJI5O NVjjNG9SW0GQR1XS
SCLC-21H NV;yb|NbT3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm= M{\YU2lEPTB;MUW5MlQyKG6P MUfTRW5ITVJ?
NCI-H1304 MWjHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>? NFHGXIpKSzVyPUG2PU4zOSCwTR?= NHf3OHNUSU6JRWK=
NCI-H510A MXPHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>? M4TWS2lEPTB;MUi1MlM4KG6P MmXmV2FPT0WU
NCI-H209 MnXES5Jwf3SqIFnubIljcXSrb36gRZN{[Xl? MV\JR|UxRTF7Nj61NkBvVQ>? NUHiclY6W0GQR1XS
KM-H2 MWjHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>? M2LyW2lEPTB;MUm3MlA2KG6P MXHTRW5ITVJ?
NCI-H1395 MX7Hdo94fGhiSX7obYJqfGmxbjDBd5NigQ>? NV7YT|l{UUN3ME2yNVAvOTNibl2= Mn3YV2FPT0WU
NCI-H1155 NEjsc5RIem:5dHigTY5pcWKrdHnvckBCe3OjeR?= MlGyTWM2OD1{M{CuN|Ihdk1? NFz5S3lUSU6JRWK=
COR-L279 MXvHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>? NEDzNXlKSzVyPUK1Nk4yPyCwTR?= MY\TRW5ITVJ?
NCI-H1299 Ml7GS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl? NHHwZ5dKSzVyPUK2NU44OSCwTR?= M4TJPHNCVkeHUh?=
EW-22 NFG2fmxIem:5dHigTY5pcWKrdHnvckBCe3OjeR?= MVXJR|UxRTJ4Mz63OUBvVQ>? NFG4UJNUSU6JRWK=
SK-MEL-2 NYP4bXk2T3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm= MYjJR|UxRTJ6MT65JI5O NFHndY5USU6JRWK=
KASUMI-1 M3;HOmdzd3e2aDDJcohq[mm2aX;uJGF{e2G7 NHTmdZpKSzVyPUK4N{4xPSCwTR?= NYK2W3oxW0GQR1XS
NCI-H187 MXXHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>? M{fqXWlEPTB;Mki3MlA5KG6P MWnTRW5ITVJ?
NCI-H2171 NVHMWXJlT3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm= MmXiTWM2OD1{OEiuPVIhdk1? M3y0c3NCVkeHUh?=
LNCaP-Clone-FGC MYXHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>? NHvycmZKSzVyPUK5OU4zPiCwTR?= NX7rRWhxW0GQR1XS
NCI-H1522 NXHsUlg4T3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm= MWXJR|UxRTNyNz6wOUBvVQ>? MVfTRW5ITVJ?
SCH MX;Hdo94fGhiSX7obYJqfGmxbjDBd5NigQ>? NWnDfWUzUUN3ME2zNlIvOjJibl2= NISzXIxUSU6JRWK=
THP-1 NYT1[G1LT3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm= NEfvVlZKSzVyPUOyNk43KG6P MofJV2FPT0WU
SNU-C1 NWCzSHZHT3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm= M1zLdmlEPTB;M{[yMlA6KG6P MlnYV2FPT0WU
CA46 NIC5dmtIem:5dHigTY5pcWKrdHnvckBCe3OjeR?= MX;JR|UxRTN5Mz62N{BvVQ>? NWT1eo92W0GQR1XS
NCI-H1963 M4K1R2dzd3e2aDDJcohq[mm2aX;uJGF{e2G7 MXfJR|UxRTN6Nj6xPUBvVQ>? NIP5d3pUSU6JRWK=
DEL MVrHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>? MYTJR|UxRTN7MT6yO{BvVQ>? NWX2RphGW0GQR1XS
TUR MU\Hdo94fGhiSX7obYJqfGmxbjDBd5NigQ>? NV2ySVl6UUN3ME2zPVYvPjFibl2= NVTDU5RFW0GQR1XS
NCI-H226 M2XvSWdzd3e2aDDJcohq[mm2aX;uJGF{e2G7 M1\pTmlEPTB;NECzMlI{KG6P NUXQdIZ7W0GQR1XS
COLO-668 NF7lT49Iem:5dHigTY5pcWKrdHnvckBCe3OjeR?= NHux[ldKSzVyPUSwN{42PyCwTR?= MnS4V2FPT0WU
CPC-N MnK1S5Jwf3SqIFnubIljcXSrb36gRZN{[Xl? MkP0TWM2OD12MEOuO|chdk1? MWrTRW5ITVJ?
NCI-H889 Mn\6S5Jwf3SqIFnubIljcXSrb36gRZN{[Xl? Ml3yTWM2OD12NkGuPVIhdk1? NHT6NW1USU6JRWK=
J-RT3-T3-5 MUDHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>? M3fITGlEPTB;NUOyMlU4KG6P NX7xbHZSW0GQR1XS
MSTO-211H NUjWS|BuT3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm= NIrLeZZKSzVyPUW3OE4zPiCwTR?= M1vlfXNCVkeHUh?=
SCC-15 MnjjS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl? MljTTWM2OD14NkeuOFchdk1? M4mwOHNCVkeHUh?=
SUP-T1 NUHkXnpjT3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm= NHrCXlJKSzVyPU[4Ok4xPCCwTR?= MXTTRW5ITVJ?
DMS-153 NF;qSI5Iem:5dHigTY5pcWKrdHnvckBCe3OjeR?= NHXjOGdKSzVyPUe0Ok45OyCwTR?= MWTTRW5ITVJ?
MS-1 NVPHb2hiT3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm= MV7JR|UxRTd3OT60NkBvVQ>? MlriV2FPT0WU
TC-YIK MXfHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>? MnHGTWM2OD15OEGuNFEhdk1? MknrV2FPT0WU
RPMI-8866 MYLHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>? MYnJR|UxRTFyME[uNlgh|ryP MoLmV2FPT0WU
KY821 M1:zZmdzd3e2aDDJcohq[mm2aX;uJGF{e2G7 NF[3RmdKSzVyPUGwN|YvODRizszN M3TVT3NCVkeHUh?=
P31-FUJ MlvPS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl? NYm4[Y9zUUN3ME2xNVEzNjd3IN88US=> MYfTRW5ITVJ?
COLO-824 MorsS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl? NHzBb5lKSzVyPUGyOlEvPzhizszN M2H3OHNCVkeHUh?=
U-698-M NVrL[2NzT3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm= NUf0fGxWUUN3ME2yNlYzNjF3IN88US=> M3\3RnNCVkeHUh?=
TE-441-T M3nFdmdzd3e2aDDJcohq[mm2aX;uJGF{e2G7 M2PkUmlEPTB;MkWyNU44KM7:TR?= MV3TRW5ITVJ?
IMR-5 MUDHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>? MkG4TWM2OD1|NEC5MlYzKM7:TR?= NWPLfZdVW0GQR1XS
NCI-H1838 M{\FZWdzd3e2aDDJcohq[mm2aX;uJGF{e2G7 NGr1c2dKSzVyPUSxPFYvOzJizszN MnLCV2FPT0WU

他の多くの細胞株試験データをご覧になる場合はこちらをクリックして下さい
体内試験 The anticancer effects of bortezomib as a single agent have been demonstrated in xenograft models of multiple myeloma, adult T-cell leukemia, lung, breast, prostate, pancreatic, head and neck, and colon cancer, and in melanoma. [2] Oral bortezomib 1.0 mg/ kg daily for 18 days causes tumor growth delays, as well as a decrease in the number of metastases in the Lewis lung cancer model. Bortezomib at a single dose of up to 5 mg/kg significantly decreased the surviving fraction of breast tumor cells. Bortezomib 1.0 mg/kg administrated weekly for 4 weeks reduces tumor growth by 60% in murine xenograft models of prostate cancer. 1.0 mg/kg Bortezomib administration for 4 weeks results in a 72% or 84% reduction in pancreatic cancer murine xenografts growth, as well as an increase in tumor cell apoptosis. 1.0 mg/kg Bortezomib treatment results in significant inhibition of human plasmacytoma xenograft growth, increase in tumor cells apoptosis and overall survival, and a decrease in tumor angiogenesis. [3]

お薦めの試験操作（参考用のみ）

キナーゼ試験：

[4]
+ 展開

Kinetic Methods:

In a typical kinetic run, 2.00 mL of assay buffer (20 mM HEPES, 0.5 mM EDTA, 0.035% SDS, pH 7.8) and Suc-Leu-Leu-Val-Tyr-AMC in DMSO are added to a 3 mL fluorescence cuvette, and the cuvette is placed in the jacketed cell holder of a fluorescence spectrophotometer. Reaction temperature is maintained at 37℃ by a circulating water bath. After the reaction solution has reached thermal equilibrium (5 minutes), 1 μL−10 μL of the stock enzyme solution is added to the cuvette. Reaction progress is monitored by the increase in fluorescence emission at 440 nm (λex= 380 nm) that accompanies cleavage of AMC from peptide-AMC substrates.
細胞試験：

[5]
+ 展開
  • 細胞株： Human multiple myeloma cells line U266
  • 濃度： ~10 μM
  • 反応時間： 2 days
  • 実験の流れ：

    The inhibitory effect of Bortezomib on cell growth is assessed by measuring MTT dye absorbance of the cells. Cells from 48-hour cultures are pulsed with 10 μL of 5 mg/mL MTT to each well for the last 4 hour of 48-hour cultures, followed by 100 μL of isopropanol containing 0.04 N HCl. Absorbance is measured at 570 nm using a spectrophotometer.


    (参考用のみ)
動物試験：

[3]
+ 展開
  • 動物モデル： Human plasmacytoma xenografts RPMI 8226
  • 製剤： Saline
  • 投薬量： 1 mg/kg
  • 投与方法： i.v. twice weekly for 4 weeks, then once weekly
    (参考用のみ)

溶解度 (25°C)

体外 DMSO 76 mg/mL (197.79 mM)
Water Insoluble
Ethanol Insoluble
体内 左から（NMPから）右の順に溶剤を製品に加えます(文献ではなく、Selleckの実験によるデータ):
2% DMSO+30% PEG 300+ddH2O
混合させたのち直ちに使用することを推奨します。 		5mg/mL

* 溶解度測定はSelleck技術部門によって行われており、その他文献に示されている溶解度と差異がある可能性がありますが、同一ロットの生産工程で起きる正常な現象ですからご安心ください。

化学情報

分子量 384.24
化学式

C19H25BN4O4
CAS No. 179324-69-7
保管 粉
in solvent
別名 LDP-341, MLM341

便利ツール

モル濃度計算器

モル濃度計算器

求めたい質量、体積または濃度を計算してください。

質量 (g) = 濃度 (mol/L) x 体積 (L) x 分子量 (g/mol)

モル濃度計算器方程式

  • 質量
    濃度
    体積
    分子量

*貯蔵液を準備するとき、常に、オンであるとわかる製品のバッチに特有の分子量を使って、を通してラベルとMSDS/COA（製品ページで利用可能な）。

希釈計算器

希釈計算器

貯蔵液を準備するために必要な希釈率を計算してください。Selleck希釈計算器は、以下の方程式に基づきます：

開始濃度 x 開始体積 = 最終濃度 x 最終体積

希釈の計算式

この方程式は、一般に略語を使われます：C1V1 = C2V2 ( 入力 出力 )

  • C1
    V1
    C2
    V2

常に貯蔵液を準備するとき、小びんラベルとMSDS/COA（オンラインで利用できる）で見つかる製品のバッチに特有の分子量を使ってください。

連続希釈計算器方程式

  • 連続希釈剤

  • 計算結果

  • C1=C0/X C1: LOG(C1):
    C2=C1/X C2: LOG(C2):
    C3=C2/X C3: LOG(C3):
    C4=C3/X C4: LOG(C4):
    C5=C4/X C5: LOG(C5):
    C6=C5/X C6: LOG(C6):
    C7=C6/X C7: LOG(C7):
    C8=C7/X C8: LOG(C8):
分子量計算器

分子量计算器

そのモル質量と元素組成を計算するために、合成物の化学式を入力してください：

総分子量：g/mol

チップス: 化学式は大文字と小文字の区別ができます。C10H16N2O2 c10h16n2o2

モル濃度計算器

質量 濃度 体積 分子量

臨床試験

NCT Number Recruitment Conditions Sponsor/Collaborators Start Date Phases
NCT03607643 Not yet recruiting Cancer of Pancreas|Cancer of Liver|Cancer of Rectum|Cancer of Colon|Cancer Gall Bladder|Myeloma Multiple|Glioblastoma Multiforme Leaf Vertical Inc. January 15 2019 Phase 1|Phase 2
NCT03701321 Not yet recruiting Recurrent Plasma Cell Myeloma|Refractory Plasma Cell Myeloma National Cancer Institute (NCI) January 25 2019 Phase 1|Phase 2
NCT03729804 Not yet recruiting Multiple Myeloma University of Chicago December 24 2018 Phase 3
NCT03651128 Not yet recruiting Multiple Myeloma Celgene November 30 2018 Phase 3
NCT03737136 Recruiting Antibody-mediated Rejection Shahid Beheshti University of Medical Sciences November 1 2018 Not Applicable
NCT03652064 Not yet recruiting Multiple Myeloma Janssen Research & Development LLC November 26 2018 Phase 3

技術サポート

ストックの作り方、阻害剤の保管方法、細胞実験や動物実験の際に注意すべき点など、製品を取扱う時に問い合わせが多かった質問に対しては取扱説明書でお答えしています。

Handling Instructions

他に質問がある場合は、お気軽にお問い合わせください。

  • * 必須

よくある質問（FAQ）

  • 質問1：

    On your website, it is mentioned that Bortezomib should be prepared at a concentration of 5 mg/ml in 2% DMSO/30% PEG300/ddH2O for in vivo use. But on the product sheet we received with the compound, it is mentioned: 5mg/ml in 0.5% methylcellulose, 0.2% tween 80. So which is the correct preparation buffer?

  • 回答：

    S1013 Bortezomib in 2% DMSO+30% PEG 300+ddH2O at 5 mg/ml is a clear solution, and it in 0.5% methylcellulose+0.2% Tween 80 is a suspension. Please choose the suitable vehicle according to your administration route. When you prepare the clear solution, please dissolve Bortezomib in DMSO first, make sure it dissolves well, warm it up to 45 degree and/or sonicate if necessary, then add PEG, mix well, and finally add water.

selleck catalog

Proteasomeシグナル伝達経路

Proteasome Inhibitors with Unique Features

  • Pan Proteasome Inhibitor

    Ixazomib (MLN2238) : β5 site, IC50=3.4 nM; β1 site, IC50=31 nM; β2 site, IC50=3500 nM.

  • FDA-approved Proteasome Inhibitor

    Carfilzomib (PR-171) : Approved by FDA for multiple myeloma.

  • Newest Proteasome Inhibitor

    Oprozomib (ONX 0912) : Orally bioavailable inhibitor for CT-L activity of 20S proteasome β5/LMP7 with IC50 of 36 nM/82 nM.

  • Classic Proteasome Inhibitor

    ONX-0914 (PR-957) : Selective immunoproteasome inhibitor with minimal cross-reactivity for the constitutive proteasome.

相関Proteasome製品

  • VR23

    VR23 is a potent proteasome inhibitor with IC50 of 1 nM, 50-100 nM, and 3 μM for trypsin-like proteasomes, chymotrypsin-like proteasomes, and caspase-like proteasomes, respectively.

  • Calpeptin

    Calpeptin is a potent, cell-permeable calpain inhibitor with ID50 of 52 nM, 34 nM, 138 nM, and 40 nM for Calpain I (porcine erythrocytes), Calpain II (porcine kidney), Papainb, and Calpain I (human platelets), respectively.

  • Marimastat (BB-2516)

    Marimastat (BB-2516) is a broad spectrum matrix metalloprotease (MMP) inhibitor for MMP-9, MMP-1, MMP-2, MMP-14 and MMP-7 with IC50 of 3 nM, 5 nM, 6 nM, 9 nM and 13 nM, respectively. Phase 3.

  • MG-132

    MG132 is a potent cell-permeable proteasome and calpain inhibitor with IC50s of 0.1 and 1.2 μM for the inhibition of proteasome and calpain, respectively.

  • Carfilzomib (PR-171)

    Carfilzomib (PR-171) is an irreversible proteasome inhibitor with IC50 of <5 nM in ANBL-6 cells, displayed preferential in vitro inhibitory potency against the ChT-L activity in the β5 subunit, but little or no effect on the PGPH and T-L activities.

  • Ixazomib (MLN2238)

    MLN2238 inhibits the chymotrypsin-like proteolytic (β5) site of the 20S proteasome with IC50 and Ki of 3.4 nM and 0.93 nM in cell-free assays, respectively, also inhibits the caspase-like (β1) and trypsin-like (β2) proteolytic sites, with IC50 of 31 and 3500 nM. Phase 3.

    Features:A first-in-class proteasome inhibitor that has improved pharmacokinetics (PK), pharmacodynamics(PD), and antitumor activity in preclinical studies.

  • ONX-0914 (PR-957)

    ONX-0914 (PR-957) is a potent and selective immunoproteasome inhibitor with minimal cross-reactivity for the constitutive proteasome in a cell-free assay.

    Features:The first highly selective, small molecule inhibitor of the immunoproteasome. Potential use in cancer and autoimmune diseases (e.g. rheumatoid arthritis, inflammatory bowel disease, and lupus).

Tags: Bortezomib (PS-341)を買う | Bortezomib (PS-341) ic50 | Bortezomib (PS-341)供給者 | Bortezomib (PS-341)を購入する | Bortezomib (PS-341)費用 | Bortezomib (PS-341)生産者 | オーダーBortezomib (PS-341) | Bortezomib (PS-341)化学構造 | Bortezomib (PS-341)分子量 | Bortezomib (PS-341)代理店
×
細胞株 試験類型 濃度 培養時間 溶剤類型 活性叙述 PMID